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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about N-nitrosodiphenylamine and 
to emphasize the human health effects that may result from exposure to it. The 
Environmental Protection Agency (EPA) has identified 1,300 sites on its National Priorities 
List (NPL). N-Nitrosodiphenylamine has been found in at least 172 of these sites. 
However, we do not know how many of the 1,300 NPL sites have been evaluated for 
N-nitrosodiphenylamine. As EPA evaluates more sites, the number of sites at which 
N-nitrosodiphenylamine is found may change. This information is important for you to 
know because N-nitrosodiphenylamine may cause harmful health effects and because these 
sites are potential or actual sources of human exposure to N-nitrosodiphenylamine. 
When a chemical is released from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment as a chemical emission. 
This emission, which is also called a release, does not always lead to exposure. You can 
be exposed to a chemical only when you come into contact with the chemical. You may 
be exposed to it in the environment by breathing, eating, or drinking substances containing 
the chemical or from skin contact with it. 
If you are exposed to a hazardous chemical such as N-nitrosodiphenylamine, several 
factors will determine whether harmful health effects will occur and what the type and 
severity of those health effects will be. These factors include the dose (how much), the 
duration (how long), the route or pathway by which you are exposed (breathing, eating, 
drinking, or skin contact), the other chemicals to which you are exposed, and your 
individual characteristics such as age, sex, nutritional status, family traits, life style, and 
state of health. 
1 .1 WHAT IS N-NITROSODIPHENYLAMINE? 
N-Nitrosodiphenylamine is an orange-brown or yellow solid. It evaporates slowly to the 
air and can attach to dust particles and travel with the wind. It can dissolve in water and 
attach to soil. It breaks down to other substances, but we do not know whether these 
substances are harmful to humans, We have not found N-nitrosodiphenylamine in 
drinking water, foods, or in the air we breathe. However, it is in the water and soil near 
some hazardous waste sites. We do not know whether N-nitrosodiphenylamine is found 
in the air near hazardous waste sites or in fo.od grown near such sites. 
We do not know if N-nitrosodiphenylamine occurs naturally in the environment, but some 
scientific evidence suggests that tiny organisms too small to be seen without the aid of a 
microscope may make it. It can be man-made and is used to make rubber products such 
as tires. It is sometimes used to make other chemicals. In the early 1980s most U.S. 
rubber manufacturers replaced it with more efficient chemicals. Only one manufacturer 
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in the United States produces N-nitrosodiphenylamine. See Chapter 3 for more 
information on the physical and chemical properties of N-nitrosodiphenylamine. See 
Chapter 4 for more information on its production, import, use, and disposal. 
1.2 	  WHAT HAPPENS TO N-NITROSODIPHENYLAMINE WHEN IT ENTERS THE
 ENVIRONMENT? 
N-Nitrosodiphenylamine can enter the environment by evaporating to the .air from waste 
sites. It can also leak into the ground from waste sites and dissolve into the groundwater 
and surface water. Industrial discharge releases N-nitrosodiphenylamine into water. 
N-Nitrosodiphenylamine can also bind to soil. In laboratory tests, most N-nitrosodiphenylamine 
disappears from water and soil within several weeks. Organisms that live in the 
water take it up to a limited degree. We do not know if land animals or plants take it 
up. It is believed that the chemical breaks down to other products. We do not know 
what the breakdown products are or if they are harmful to humans. However, it has not 
been found in the drinking water, food, or air with which you would normally come in 
contact. Chapters 4 and 5 contain more information on what happens to this chemical 
when it enters the environment. 
1.3 	  HOW MIGHT I BE EXPOSED TO N-NITROSODIPHENYLAMINE? 
There is no available information to show that N-nitrosodiphenylamine exists in the soil, 
air, food, or water with which you would normally come in contact. Therefore, you are 
not likely to be exposed to it. 
Workers who were or are involved in the production or use of N-nitrosodiphenylamine 
may have been exposed to t.he chemical. Occupational data from 1981 to 1983 show that 
an estimated 1,093 workers employed at 137 plants might have been exposed to it. 
Today, since only one company makes it, fewer workers are exposed. Current exposure 
may also include contact with N-nitrosodiphenylamine at hazardous waste sites. It has 
been found in 3.6% of underground water samples and 0.7% of aboveground water 
samples taken at hazardous waste sites. See Chapter 5 for more information on how you 
might be exposed to iV-nitrosodiphenylamine. 
1.4 	 HOW CAN N-NITROSODIPHENYLAMINE ENTER AND LEAVE MY BODY? 
Substances can generally enter your bloodstream if you breathe them in the air, eat or 
drink them, or get them on your skin. We do not know if N-nitrosodiphenylamine can 
enter your body through the lungs. Evidence from animal studies shows that 
N-nitrosodiphenylamine enters the bloodstream after animals swallow water or food 
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exposed to it by mouth. Animal studies also suggest that N-nitrosodiphenylamine can 
enter your body if it gets on your skin. If you live near a hazardous waste site, 
N-nitrosodiphenylamine could enter your body if you drink water containing it or possibly 
if you breathe it in the air. Children could also be exposed by eating or touching dirt 
that has N-nitrosodiphenylamine in it. If you work with N-nitrosodiphenylamine, you could 
be exposed to it by breathing small particles of it in the air or getting it on your skin. 
Animals break N-nitrosodiphenylamine down into other substances that can also harm 
their health. We expect that humans break it down by similar means. 
An animal study showed that some N-nitrosodiphenylamine rapidly leaves the body in 
urine. Some probably also leaves the body in feces. It probably leaves the human body 
in a similar manner. We do not how long it takes for all N-nitrosodiphenylamine to leave 
the body. 
It is most likely to enter your body if you come into contact with it in air, water, or soil 
at hazardous waste sites containing it. For more information on how it enters and leaves 
your body see Chapter 2. 
1.5 	 HOW CAN N-NITROSODIPHENYLAMINE AFFECT MY HEALTH? 
We do not have enough information to know how N-nitrosodiphenylamine will affect your 
health. 
We know very little about the health effects of exposure to N-nitrosodiphenylamine in 
animals, except that swallowing large doses can cause death. Animals given N-nitrosodiphenylamine 
in their diets for long periods developed swelling, cancer of the bladder, 
and changes in body weight.. We do not know whether these effects would occur in 
humans. We also do not know if it can affect pregnancy or cause birth defects. EPA 
considers N-nitrosodiphenylamine to be a possible cancer-causing substance in humans 
because of the health effects seen in some animals. The International Agency for 
Research on Cancer (IARC) concluded that there are not enough data to determine 
whether Nnitrosodiphenylamine causes cancer in humans. IARC also concluded that 
there is limited evidence indicating that N-nitrosodiphenylamine causes cancer in 
experimental animals. 
1.6 	   IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
 EXPOSED TO N-NITROSODIPHENYLAMINE? 
There are no tests available to determine if you have been exposed to N-nitrosodiphenylamine. 
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the blood and urine of exposed animals, but these tests have not been used for people. 
Refer to Chapters 2 and 6 for more information on these tests in animals. 
1.7 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government has taken steps to protect you from N-nitrosodiphenylamine. If 
amounts over 100 pounds are released to the environment, the National Response Center 
of the federal government must be told immediately. According to EPA, the amount of 
N-nitrosodiphenylamine in water (lakes, rivers, etc.) should be limited to 49,000 nanograms 
(one billionth of a gram) per liter of water or less. At these amounts, EPA estimates that 
your risk of getting cancer is very low. The amount in drinking water should be 
700 micrograms (one millionth of a gram) per liter or less. 
Chapter 7 contains more information on recommendations to protect human health. 
1.8 	     WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state 
health or environmental quality department or: 








This agency can also provide you with information on the location of the nearest 
occupational and environmental health clinic. These clinics specialize in the recognition, 








The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other 
interested individuals and groups with an overall perspective of the toxicology of N-nitrosodiphenylamine 
and a depiction of significant exposure levels associated with various adverse health effects. It contains 
descriptions and evaluations of studies and presents levels of significant exposure for N-nitrosodiphenylamine 
based on toxicological studies and epidemiological investigations. 
2.2   DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals address the needs of persons living or working near hazardous waste 
sites, the information in this section is organized first by route of exposure--inhalation, oral, and dermal--
and then by health effect--death, systemic, immunological, neurological, developmental, reproductive, 
genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure periods--acute 
(14 days or less), intermediate (15-364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. 
The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverseeffect 
levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have 
heen classified into “less serious” or “serious” effects. These distinctions are intended to help the users of . 
the document identify the levels of exposure at which adverse health effects start to appear. They should 
also help to determine whether or not the effects vary with dose and/or duration, and place into 
perspective the possible significance of these effects to human health. 
The significance of the exposure levels shown in the tables and figures may differ depending on the user’s 
perspective. For example, physicians concerned with the interpretation of clinical findings. in exposed 
persons may be interested in levels of exposure associated with “serious” effects. Public health officials and 
project managers concerned with appropriate actions to take at hazardous waste sites may want information 
on levels of exposure associated with more subtle effects in humans or animals (LOAEL) or exposure 
levels below which no adverse effects (NOAEL) have been observed. Estimates of levels posing minimal 
risk to humans (Minimal Risk Levels, MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with the carcinogenic effects of N-nitrosodiphenylamine are indicated in 
Figure 2-l. Because cancer effects could occur at lower exposure levels, the figures also show a range for 
the upper bound of estimated excess risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 
l0-7), as developed by EPA. 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made, where data were 
believed reliable, for the most sensitive noncancer effect for each exposure duration. MRLs include 
adjustments to reflect human variability and extrapolation of data from laboratory animals to humans. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1989a), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 






2.2.1     Inhalation Exposure 
2.2.1.1   Death 
No studies were located regarding death in humans or animals after inhalation exposure to N-nitrosodiphenylamine. 
2.2.1.2     Systemic Effects 
No studies were located regarding cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, 
renal, or dermal/ocular effects in humans or animals after inhalation exposure to N-nitrosodiphenylamine. 
Respiratory Effects.   No studies were located regarding respiratory effects in humans after inhalation 
exposure to N-nitrosodiphenylamine. 
Rats exposed to 350-400 mg/m3 Vulkalent A (N-nitrosodiphenylamine) dust for 2 hours per day were 
observed to have catarrhal bronchitis of the lungs (Zhilova and Kasparov 1966). Interpretation of the 
results of this study is not possible because of severe limitations in the experimental procedure and 
presentation of data. The limitations include insufficient reporting of experimenta! details and data, use 
of unspecified strains and an undefined control group, and lack of statistical analyses. 
2.2.1.3 Immunological Effects 
No studies were located regarding immunological effects in humans after inhalation exposure to 
N-nitrosodiphenylamine. 
Reduced phagocytic activity of the leukocytes was reported in rats exposed to 350-400 mg/m3 Vulkalent A 
(N-nitrosodiphenylamine) dust for 2 hours per day for 20 days (Zhilova and Kasparov 1966). Interpretation 
of these results is not possible because of severe limitations in the experimental procedure. These 
limitations are discussed in Section 2.2.1.2. 
2.2.1.4 Neurological Effects 
No studies were located regarding neurological effects in humans after inhalation exposure to N-
nitrosodiphenylamine. 
A lengthening of the chronaxie of the extensors of the rear extremities was observed in rats exposed to 
350-400 mg/m3Vulkalent A (N-nitrosodiphenylamine) dust for 2 hours per day for 20 days (Zhilova and 
Kasparov 1966). Interpretation of these results is not possible because of severe limitations in the 







No studies were located regarding the following health effects in humans or animals after inhalation 
exposure to N-nitrosodiphenylamine: 
2.2.1.5 Developmental Effects 
2.2.1.6  Reproductive Effects 
2.2.1.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.4. 
2.2.1.8 Cancer 
No studies were located regarding cancer in humans or animals after inhalation exposure to N-
nitrosodiphenylamine. 
2.2.2 Oral Exposure 
2.2.2.1 Death 
No studies were located regarding death in humans after oral exposure to N-nitrosodiphenylamine. 
Only two studies on the acute oral toxicity of N-nitrosodiphenylamine in animals were located. Acute oral 
LD50 values of 3,000 mg/kg and 3,850 mg/kg were determined for rats (Druckrey et al. 1967) and mice 
(Zhilova and Kasparov 1966) respectively. However, details on the methodology for these experiments 
were limited and detailed data were not presented. 
Data from an intermediate-duration range-finding study provide lethality data for intermediate exposure 
(NCI 1979). Groups of five Fischer-344 rats of each sex and five B6C3F1 mice of each sex were used in 
these studies. Male rats were fed diets containing 0-500 mg,/kg/day of N-nitrosodiphenylamine for 
11 weeks, and female rats were fed diets containing 0-2,300 mg/kg/day for 8 weeks. No deaths occurred 
in exposed male rats or in female rats given doses of <800 mg/kg/day (NOAEL of 500 mg/kg/day for male 
rats and 400 mg/kg/day for female rats). Two of five female rats died at 800 mg/kg/day (a LOAEL), and 
mortality was 100% at dietary levels of >800 mg/kg/day. In another intermediate-duration study, 
N-nitrosodiphenylamine in an aqueous methylcellulose vehicle was administered by gavage to 25 male 
Wistar rats at a dose of 3.1 mg/kg/day, 5 days per week, for 45 weeks (Argus and Hoch-Ligeti 1961). All 
rats survived until termination of the study at 53 weeks. This study provides limited information since no 
control groups were used and only one concentration was tested. The doses of N-nitrosodiphenylamine 
incorporated into the diet of male and female mice ranged from 0 to 5,980 mg/kg/day for 8 weeks (NCI 
1979). All mice survived at all dietary levels including the highest tested. These data indicate that rats 
are more sensitive to the lethal effects of iV-nitrosodiphenylamine than are mice since the dose that 
produced 100% mortality in rats had no effect on survival in mice. 
Decreased survival was observed in rats and mice chronically exposed to N-nitrosodiphenylamine in their 
diet for 98-101 weeks (Cardy et al. 1979; NCI 1979). As in the intermediate-duration study, rats were 
found to be more sensitive to the lethal effects of the chemical than mice. The females of both species 
were more sensitive to the lethal effects of chronic exposure to N-nitrosodiphenylamine than the males. 
Fischer-344 rats of both sexes were fed diets that contained 50 or 200 mg/kg/day of N-nitrosodiphenylamine 
for 1ClCl weeks. Male B6C3F1 mice were fed diets that contained 1,300 or 2,600 mg/kg/day for 101 weeks. 
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to 130 and 520 mg/kg/day at 38 weeks because of the drastic reduction in body weight experienced at the 
higher doses. The reduced doses were continued for 60 additional weeks. The time-weighted average 
(TWA) concentrations for female mice over the 98 total weeks of the experiment were calculated to be 
301 and 711 mg/kg/day. There were no significant treatment-related effects on survival in the male rats 
or male mice (NOAELs of 200 and 2,600 mg/kg/day for male rats and male mice, respectively). Survival 
was dose-related in the female rats, with a marginal reduction in survival at 50 mg/kg/day (NOAEL) and 
a more marked reduction at 200 mg/kg/day (LOAEL). In female mice, there was no dose-related survival 
trend; however, survival in the high-dose group was greatly reduced (LOAEL of 711 mg/kg/day) compared 
with that in low-dose (NOAEL of 30 mg/kg/day) and control groups. 
All reliable LOAEL values for death in each species and duration category are recorded in Table 2-l and 
plotted in Figure 2-l. 
2.2.2.2 Systemic Effects 
No studies were located regarding systemic effects in humans after oral exposure to N-nitrosodiphenylamine. 
The highest NOAEL values and all reliable LOAEL values for systemic effects in rats and mice following 
acute, intermediate, and chronic exposure are recorded in Table 2-l and plotted in Figure 2-l. 
Respiratory Effects.   In an intermediate-duration gavage study, N-nitrosodiphenylamine in an aqueous 
methylcellulose vehicle was administered to 25 male Wistar rats at a dose of 3.1 mg/kg/day, 5 days/week, 
for 45 weeks (Argus and Hoch-Ligeti 1961). The rats were killed after an additional &week observation 
period. Histological examination of the lungs revealed peribronchial lymphocytic infiltration, which the 
authors described as common in older rats. Squamous metaplasia of the bronchial epithelium, particularly 
in areas of bronchiectasis, was observed in some of the lungs. Peribronchial pneumonia and emphysema 
were observed in rabbits administered 20 mg/kg Vulkalent A (N-nitrosodiphenylamine) intragastrically for 
4 months (Zhilova and Kasparov 1966). It could not be determined if the respiratory effects observed in 
these studies were associated with N-nitrosodiphenylamine exposure since incidences were not reported and 
control groups either were not used or were not clearly defined. However, no treatment-related histological 
lesions of the lungs, bronchi, or trachea were observed in intermediate- and chronic-duration studies in 
which rats and mice were administered doses as high as 5,980 mg/kg/day for periods up to 101 weeks (NCI 
1979). 
Cardiovascular Effects. No treatment-related histological effects of the heart were reported in a chronic 
study of rats and mice administered N-nitrosodiphenylamine in their food (NCI 1979). No functional 
studies were performed that might provide data supporting the histological evidence. 
Gastrointestinal Effects.   No treatment-related histological effects of the gastrointestinal system 
(esophagus, stomach, intestines, pancreas) were reported in a chronic study of rats and mice administered 
N-nitrosodiphenylamine in their food (NCI 1979). No functional studies were performed that might 
provide data supporting the histological evidence. 
Hematological Effects.   No treatment-related histological effects of the bone marrow were reported in 
a chronic study of rats and mice administered N-nitrosodiphenylamine in their food (NCI 1979). No 



















Musculoskeletal Effects. No treatment-related histological effects of the musculoskeletal system were 
reported in a chronic study of rats and mice administered N-nitrosodiphenylamine in their food (NCI 1979). 
The specific tissues examined were not reported and no studies of function were performed. 
Hepatic Effects. The limited data available indicate that the liver is not a target organ for N-
nitrosodiphenylamine toxicity. In an acute study of hepatotoxicity (Nishie et al. 1972), mice given 350 mg/kg/day 
of N-nitrosodiphenylamine for 4 consecutive days preceding, or one dose 24 hours prior to, pentobarbital 
administration had effects characteristic of liver enzyme induction. These effects consisted of significantly 
decreased pentobarbital sleeping time, and increased amounts of smooth endoplasmic reticulum among granules of 
glycogen in the liver cells. Electron microscopy also revealed blebs, hypertrophy, and 
pleomorphism of the mitochondria. A NOAEL of 350 mg/kg/day was identified for hepatic effects, since 
no hepatic lesions were revealed by light microscopy. 
In an 8-week feeding study in rats and mice (NCI 1979), the only gross or histopathological effect reported 
for the liver was pigmentation of Kupffer’s cells in the hepatic sinusoids in male mice that received 
5,980 mg/kg/day of N-nitrosodiphenylamine. However, according to the tabular data presented, only female 
mice received this dose; the highest dose in male mice was reported as 2,860 mg/kg/day. There is no way 
to determine which data are incorrect. In any case, the pigmentation was presumed to reflect phagocytic 
activity by the Kupffer’s cells. It was not considered to be adverse because only trace amounts occurred, 
there were no signs of toxicity or other histological alterations, and survival was not affected. In addition, 
no adverse liver effects were reported in rats from the same study (NCI 1979) even though rats appear 
more sensitive to the toxic effects of N-nitrosodiphenylamine than mice. Fatty and granular degeneration 
of the liver was reported in rabbits given 20 mg/kg Vulkalent A (N-nitrosodiphenylamine) for 4 months 
(Zhilova and Kasparov 1966). The limitations of this study are described in the discussion of renal effects 
in Section 2.2.2.2. 
Chronic studies conducted by NCI (1979) revealed no treatment-related histological effects on the livers 
of exposed rats and mice. Only histological data are available and no studies of function, which might have 
revealed more subtle changes, were performed. 
Renal Effects. In an intermediate-duration gavage study, N-nitrosodiphenylamine in an aqueous methylcellulose 
vehicle was administered to 25 male Wistar rats at a dose of 3.1 mg/kg/day, 5 days/week, for 
45 weeks (Argus and Hoch-Ligeti 1961). The rats were killed after an additional g-week observation 
period. Histological examination of the kidneys revealed albuminous precipitation in the tubules of “many” 
kidneys. The significance of this finding in the kidneys is uncertain because incidences were not reported 
and control groups were not included. Albuminous degeneration of the epithelium of the kidneys was also 
observed in rabbits administered 20 mg/kg for 4 months (the frequemy of administration was not specified) 
(Zhilova and Kasparov 1966). This experiment was severely limited because the strains used were not 
specified, the nature of control groups was uncertain, there were no statistical analyses of data, information 
on critical experimental details was lacking, and no quantitative data were presented. 
Data from chronic-duration studies in rats and mice indicate that the bladder is a target organ for chronic 
oral exposure to N-nitrosodiphenylamine. Epithelial hyperplasia of the urinary bladder increased in : 
frequency with dose in both male and female rats given doses of 50 and 200 mg/kg/day 
N-nitrosodiphenylamine in their diet for approximately 2 years (Cardy et al. 1979; NCI 1979). Squamous 
metaplasia of the bladder, a more serious lesion, occurred at low incidences and only in the high-dose animals. It is 
likely that the bladder hyperplasia and metaplasia were preneoplastic effects since transitional cell carcinoma also 









Effects on the bladder from chronic exposure to N-nitrosodiphenylamine also occurred in mice (Cardy et
 
al. 1979; NCI 1979). Male mice received 1,300 or 2,600 mg/kg/day N-nitrosodiphenylamine in the diet for
 
101 weeks, and females received 301 or 711 mg/kg/day (TWA concentrations) in the diet for 98 weeks (see
 
Section 2.2.2.1 for details of female dosing). Incidences of submucosal inflammation of the urinary bladder
 
in the control, low-dose, and high-dose groups were 0/18, 12/49, and 31/46, respectively, in the males and
 
0/18, 31/47, and, 30/38, respectively, in the females. The inflammatory response was associated with
 
connective tissue degeneration in the submucosa. Epithelial hyperplasia of the bladder in the control, lowdose, and
 
high-dose groups occurred in 0/18, 2/49, and 7/46 males, respectively, and 0/18, 3/47, and
 
6/38 females, respectively, but increased incidences of bladder neoplasms were not statistically significant.
 




Dermal/Ocular Effects.  Following chronic exposure to N-nitrosodiphenylamine, grossly observable cornea1
 
opacity occurred at higher incidences in the high-dose male rats (15/50) and low-dose female rats (16/50)
 
than in the corresponding control males (0/20) and control females (l/20) (NCI 1979). While the authors
 
concluded that this effect may have been related to treatment, the results should be viewed with caution.
 
Incidences in the low-dose males and high-dose females were not reported, and no histopathological
 
findings were recorded for the cornea.
 
Other Systemic Effects. In an intermediate-duration range-finding study, rats showed a decrease in body
 
weight of >l0% at doses of 200 mg/kg/day or more in their food (NCI 1979). Mean body weight in male
 
rats was 12% less than the controls at 200 mg/kg/day and 16% less than the controls at the high dose
 
(500 mg/kg/day). Mean body weight in female rats was 14% less than in the control group at the lowest
 
dose (200 mg/kg/day) and was 37% less than the control group at the highest dose (800 mg/kg/day) at
 
which animals survived (only two of five survived at this dose). The decreased body weight may not be
 
indicative of an adverse effect because it is not clearly related to dose and the pathologic data do not show
 
tissue damage. However, full evaluation of the significance of the body weight depression is precluded
 
because of the lack of food consumption data. The LOAEL for male and female rats was 200 mg/kg/day.
 
A NOAEL of 150 mg/kgjday was determined for male rats. Body weights in mice exposed to concentrations
 
of 0-5,980 mg/kg/day for 8 weeks were decreased (<14% depression) in a sporadic manner that does
 
not appear to be related to treatment (NCI 1979). No histopathological lesions were observed in the
 
salivary glands, pituitary, adrenals, or thyroid of rats and mice chronically exposed to
 
N-nitrosodiphenylamine in their food (NCI 1979).
 
Dose-related decreases in body weight were also reported in a chronic study (NCI 1979). Both exposure
 
groups of rats and mice showed reduced body weight gain and reduced terminal body weight compared to
 
control groups. A LOAEL of 50 mg/kg/day was determined for male and female rats. LOAELs of
 
301 and 1,300 mg/kg/day for reduced body weight were determined.for female and male mice, respectively.
 
2.2.2.3 immunological Effects 
No studies were located regarding immunological effects in humans after oral exposure to 
N-nitrosodiphenylamine. 
No treatment-related histological effects of the immunological system (spleen, lymph nodes, thymus) were 
reported in a chronic study of rats and mice administered N-nitrosodiphenylamine in their food (NCI 1979). 
No functional studies were performed that might provide data supporting the histological evidence. 
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2.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to 
N-nitrosodiphenylamine. 
No treatment-related histological effects were reported in the brains of rats and mice chronically exposed 
to N-nitrosodiphenylamine in their food (NCI 1979). No functional studies were performed that might 
provide data supporting the histological evidence. 
2.2.2.5 Developmental Effects 
No studies were located regarding developmental effects in either humans or animals after oral exposure 
to N-nitrosodiphenylamine. 
2.2.2.6 Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to N-nitrosodiphenylamine. 
No treatment-related histological effects of the testes, prostate, uterus, or ovaries were reported in a 
chronic study of rats and mice administered N-nitrosodiphenylamine in their food (NCI 1979). No 
functional studies were performed that might provide data supporting the histological evidence. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans after oral exposure to 
N-nitrosodiphenylamine. 
Male mice given oral doses of N-nitrosodiphenylamine at 500 mg/kg showed no significant signs of 
testicular deoxyribonucleic acid (DNA) synthesis depression (Friedman and Staub 1976). Negative results 
were also obtained in a liver DNA fragmentation test in which male Sprague-Dawley rats were exposed 
to 540 mg/kg of N-nitrosodiphenylamine (Brambilla et al. 1987). 
Other genotoxicity studies are discussed in Section 2.4. 
2.2.2.8 Cancer 
No studies were located regarding cancer in humans after oral exposure to N-nitrosodiphenylamine. 
One intermediate-duration study was located in which 25 male Wistar rats received N-nitrosodiphenylamine 
in an aqueous methylcellulose vehicle by gavage at a dose of 11.63 mg/kg/day, 5 days per week, for 
45 weeks (Argus and Hoch-Ligeti 1961). No tumors were found in the treated animals. Histological 
examinations were limited to the liver, spleen, kidneys, lungs, and organs with gross abnormalities. 
Rats were more sensitive than mice to the carcinogenic effects of N-nitrosodiphenylamine according to an 
NCI (1979) study. N-Nitrosodiphenylamine was administered in the diet of Fischer-344 rats and B6C3F1 mice 





    
 






     
  






(Cardy et al. 1979; NCI 197Y). Comprehensive gross and histopathological examinations were conducted 
on animals that died during the study and on all animals that survived to the end of the study. The 
highest incidence of tumors was found in the urinary bladder of rats. 
Rats received 50 and 200 mg/kg/day N-nitrosodiphenylamine in the diet for 100 weeks (Cardy et al. 1979; 
NCI l979). A significant increase (p<0.001) in the incidence of transitional cell carcinomas in the urinary 
bladder occurred in rats receiving the highest dose (an increase of 38% in males and 86% in females) 
compared to the controls. An increase in fibromas of the integumentary system (i.e., subcutis and skin) 
occurred in male rats, but this increase was not statistically significant. The authors believe that the 
occurrence of these fibromas was associated with treatment because integumentary system fibromas were 
rare in historical controls at the same laboratory. The results of the study are sufficient to conclude that 
N-nitrosodiphenylamine is carcinogenic in male and female Fischer-344 rats. A carcinogenic potency factor 
for humans (q1*) of 4.92×103(mg/kg/day)-1 has been calculated by EPA (EPA 1980b) based on these 
findings. Using this q1* estimated doses corresponding to individual lifetime upper-bound limits for 
increased risk of cancer have been calculated. These levels, 2×10-2 and 2×10-5 mg/kg/day, for increased risk 
in 1/10,000 and 1/100,000 people, respectively, are displayed graphically in Figure 2-l. 
An earlier study reported negative results in rats; however, uncertainties are associated with the study 
because the bladders were not routinely examined, smaller groups of rats were studied, and doses were 
lower than those provided by the NCI (1979) dietary levels. N-Nitrosodiphenylamine was administered to 
20 BD rats of unspecified sex in drinking water that provided a daily dose of 120 mg/kg and a total dose . 
of 65,000 mg/kg (Druckrey et al. 1967). Histopathologic examinations consisting of gross evaluation of the 
liver, brain, and unspecified organs were conducted after 700 days, but there was no evidence of tumors 
in the treated animals. 
Male B6C3F1 mice were fed 1,300 or 2,600 mg/kg/day N-nitrosodiphenylamine for 101 weeks (Cardy et al. 
1979; NCI 1979). Female B6C3F 1mice initially received 650 or 1,300 mg/kg/day for 38 weeks, but because 
of an excessive reduction in mean weight gain, dosing was discontinued for 3 weeks and then resumed at 
130 or 520 mg/kg/day for 60 weeks. TWAs of 301 and 711 mg/kg/day were determined for the low- and 
high-dose females, respectively. Transitional cell carcinoma of the bladder was reported in a low-dose male 
and female, as well as transitional cell papilloma in a high-dose male. However, there was no statistically 
significant increase in tumor incidence in the treated animals. The authors concluded that N-nitrosodiphenylamine 
was not carcinogenic in mice under the test conditions used. 
B6C3F1and B6AKF1 mice (l8sex/strain) initially received 1,000 mg/kg/day of N-nitrosodiphenylamine in 
dimethyl sulfoxide by gavage from 7 to 28 days of age, and subsequently in the diet at a concentration of 
490 mg/kg/day until 81 or 83 weeks of age (Innes et al. 1969; NCI 1968). Negative and positive controls 
were tested. An increased incidence of hepatomas, of borderline statistical significance, was observed in 
only 6 of 18 treated B6C3F 1 males. The histological examinations in this study were usually limited to 
the chest contents, liver, spleen, kidneys, adrenals, stomach, intestines, and genital organs. The bladder was 
not examined, so it is possible that results similar to those of the NCI (1979) study might have been 
obtained had the bladder been examined. The equivocal liver results from the early NCI (1968) study 
might be explained by the high percentage of liver neoplasms (30% and 20% in male and female control 
groups, respectively) found in all groups of B6C3F1 mice in the later NCI (1979) study. This strain of 









IARC has concluded that no evaluation of the carcinogenicity of N-nitrosodiphenylamine to humans is 
currently possible, and there is limited evidence for the carcinogenicity of N-nitrosodiphenylamine in 
experimental animals (IARC 1982a; 1987). 
2.2.3 Dermal Exposure 
2.2.3.1 Death 
No studies were located regarding death in humans or animals after dermal exposure to N-nitrosodiphenylamine. 
2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, 
hepatic, or renal effects in humans or animals after dermal exposure to N-nitrosodiphenylamine. 
Dermal/Ocular Effects.   No studies were located regarding dermal/ocular effects in humans after dermal 
exposure to N-nitrosodiphenylamine. 
A single dermal study was located in which mice had 0.1 mL of a 0.1% solution of N-nitrosodiphenylamine 
painted on the intrascapular region once per week for 20 weeks (Iversen 1980). The author reported that 
all painted animals had small skin ulcerations and scarring. However, the significance of the results cannot 
be determined because it was not clear if these data included the control animals painted with the acetone 
solvent or only the experimental animals. Another limitation of the experiment is the use of only one 
dose. 
No studies were located regarding the following health effects in humans or animals after dermal exposure 
to N-nitrosodiphenylamine: 
2.2.3.3 Immunological Effects 
2.2.3.4 Neurological Effects 
2.2.3.5 Developmental Effects 
2.2.3.6 Reproductive Effects 
2.2.3.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.4. 
2.2.3.8 Cancer 
No studies were located regarding cancer in humans after dermal exposure to N-nitrosodiphenylamine. 
Single weekly 0.l-mL applications of a 1% solution of N-nitrosodiphenylamine (33 mg/kg/week) in acetone 
were placed on the intrascapular region of 16 male and 24 female hairless hr/hr Oslo strain mice for 
20 weeks (Iversen 1980). Gross and histological examinations were performed on the lungs and palpable 
lesions of surviving animals (14 males, 21 females) following 80 weeks of observation. The only tumors 
detected were lung adenomas in three of the treated males. The study was limited because the treatment 
duration was short, the frequency was low, only one low exposure level was tested, histopathological 





2. HEALTH EFFECTS 
2 . 3 TOXICOKINETICS 
2.3.1  Absorption 
2.3.1.1   Inhalation Exposure 
No studies were located regarding absorption of N-nitrosodiphenylamine in humans or animals following 
inhalation exposure. 
2.3.1.2 Oral Exposure 
Specific information on the rate and extent of absorption of N-nitrosodiphenylamine in humans or animals 
following oral exposure is not available. The appearance of metabolites in the urine of rats and in the 
serum of guinea pigs following oral administration provides indirect evidence of gastrointestinal absorption 
of N-nitrosodiphenylamine (Appel et al. 19%; Tatsumi et al. 1983). Furthermore, the occurrence of 
systemic effects in rats and mice in oral carcinogenicity studies suggests that Wnitrosodiphenylamine is 
absorbed through the gastrointestinal tract in these animals (Cardy et al. 1979; NCI 1979). 
2.3.1.3 Dermal Exposure 
No studies were located regarding absorption of N-nitrosodiphenylamine in humans after dermal exposure. 
The appearance of lung adenomas in a dermal carcinogenicity study with mice provides indirect evidence 
of dermal absorption of N-nitrosodiphenylamine (Iversen 1980). 
2.3.2 Distribution 
2.3.2.1 Inhalation Exposure 
No studies were located regarding distribution of N-nitrosodiphenylamine in humans or animals after 
inhalation exposure. 
2.3.2.2 Oral Exposure 
No studies were located regarding distribution of N-nitrosodiphenylamine in humans or animals after oral 
exposure. 
2.3.2.3 Dermal Exposure 





2. HEALTH EFFECTS 
2.3.3 Metabolism 
2.3.3.1 Inhalation Exposure 
No studies were located regarding metabolism of N-nitrosodiphenylamine in humans or animals after 
inhalation exposure. 
2.3.3.2 Oral Exposure 
No studies were located regarding metabolism of N-nitrosodiphenylamine in humans after oral exposure. 
In experiments with animals, the reaction in which N-nitrosodiphenylamine is denitrosated to diphenylamine 
and nitric oxide seems to be the first step in the metabolic activation of N-nitrosodiphenylamine (Appel 
et al. 1984). A single dose of N-nitrosodiphenylamine in corn oil (1,000 mg/kg) was administered to female 
Wistar rats. Nitrate was identified as the major urinary metabolite, while nitrite, diphenylamine, and a 
monohydroxydiphenylamine were found in smaller amounts. The conclusion is that N-nitrosodiphenylamine 
is denitrosated to diphenylamine and nitric oxide. The nitric oxide is then converted into nitrite and 
nitrate. Nitrite is oxidized in substantial amounts to nitrate (Appel et al. 1984). 
In vitro studies investigated the metabolism of N-nitrosodiphenylamine in phenobarbital-induced mouse liver 
microsomes (Appel et al. 1987a, 1987b, 1987c). The metabolites found were diphenylamine, 4-
hydroxydiphenylamine, and its oxidized product, the corresponding quinoneimine. The authors conclude that 
diphenylamine undergoes ring hydroxylation to form 4-hydroxydiphenylamine which is oxidized to the 
quinoneimine. Since N-hydroxylation is recognized as the initial step in the bioactivation of carcinogenic 
arylamines, the N-hydroxy derivative of diphenylamine may be a potential metabolite. This possible 
metabolite, however, has not been detected using microsomal incubation. A postulated metabolic scheme 
based on these data is presented in Figure 2-2. 
In vitro studies conducted with rat and mouse liver cytochrome P-450 demonstrated the denitrosation of 
N-nitrosodiphenylamine (Appel et al. 1979; Schrenk et al. 1982; Wakabayashi et al. 1982). 
Transnitrosation of proline by .N-nitrosodiphenylamine occurred in male BD VI rats that were orally 
administered 28.28 mg/kg N-nitrosodiphenylamine and 50 µmol proline by gavage (Ohshima et al. 1982). 
The excretion of N-nitrosoproline was 15-fold higher than in the controls. Co-administration of thiocyanate 
had a catalytic effect, which resulted in a 58-fold increase in the urinary levels of N-nitrosoproline. 
N-Nitrosodiphenylamine can undergo reductive metabolism by liver aldehyde oxidase under anaerobic 
conditions (Tatsumi et al. 1983). Guinea pigs received oral dosages (200 mg/kg) of N-nitrosodiphenylamine. 
Just before and 3 hours after administration of N-nitrosodiphenylamine, the guinea pigs were 
treated with oral dosages (50 mg/kg) of acetaldehyde (an electron donor). Acetaldehyde diphenylhydrazone 
was identified as a plasma metabolite. 
2.3.3.3 Dermal Exposure 









2. HEALTH EFFECTS 
2.3.4 Excretion 
2.3.4.1 Inhalation Exposure 
No studies were located regarding excretion of N-nitrosodiphenylamine in humans or animals after 
inhalation exposure. 
2.3.4.2 Oral Exposure 
No studies were located regarding excretion of iV-nitrosodiphenylamine in humans after oral exposure. 
One study was located that investigated excretion in animals. After oral administration of a single 
l,000-mg/kg dose of N-nitrosodiphenylamine to female Wistar rats, the maximum urinary excretion of 
nitrate and nitrite was found 24-48 hours after administration (Appel et al. 1984). Within 36 hours of 
administration, 24.8% and 1.4% of the administered dose of N-nitrosodiphenylamine was excreted as nitrate 
and nitrite, respectively. Ninety-six hours after administration, about 30% of the administered dose had 
been eliminated as nitrite and nitrate. 
2.3.4.3 Dermal Exposure 
No studies were located regarding excretion of N-nitrosodiphenylamine in humans or animals after dermal 
exposure. 
2.3.4.4  Other Routes of Exposure 
In female Wistar rats, the maximum urinary nitrate or nitrite excretion was found in the 24 hours following 
intraperitoneal administration of 500 mg/kg N-nitrosodiphenylamine (Appel et al. 1984). This is a more 
rapid elimination than that following oral dosing. Ninety-six hours after administration, approximately 50% 
of the administered dose was detected as nitrate and nitrite--almost twice as much as was found after oral 
administration. Diphenylamine and hydroxydiphenylamine were also present as urinary metabolites. The 
rate of denitrosation after intraperitoneal injection was considerably higher than after oral administration. 
This was probably due to an altered availability of N-nitrosodiphenylamine to the liver. 
Results from a study of rats, rabbits, and guinea pigs receiving 50 mg/kg N-nitrosodiphenylamine through 
intraperitoneal injection suggested that the rate of excretion of N-nitrosodiphenylamine into the bile and 
elimination of the chemical from the bile varies among species (Atawodi and Maduagwu 1990). Guinea 
pigs showed the most rapid excretion of N-nitrosodiphenylamine into the bile. Rabbits had the slowest 
excretion of N-nitrosodiphenylamine into the bile but the most rapid elimination of the chemical from the 
bile. Both excretion to and elimination from bile were comparatively slow in the rat. The half-lives for 
N-nitrosodiphenylamine elimination from bile for these species are as follows:  95 minutes for rabbits, 
240 minutes for guinea pigs, and 510 minutes for rats. 
2.4  RELEVANCE TO PUBLIC HEALTH 
The general population is probably not exposed to N-nitrosodiphenylamine. N-Nitrosodiphenylamine is 
not a naturally occurring substance and is no longer manufactured in the United States. Although it has 
been shown to be produced by cultures of microorganisms under laboratory conditions, the extent to which 












in air, water, or soil except in contaminated areas. The major routes of exposure to N-nitrosodiphenylamine 
for humans living near hazardous waste sites are probably via inhalation of airborne dust particles 
or ingestion of contaminated water. The result of direct skin contact with soil contaminated with 
N-nitrosodiphenylamine is unclear. 
No information was located regarding toxic effects in humans following acute, intermediate, or chronic 
inhalation exposure to N-nitrosodiphenylamine; no occupational studies or case reports were located. 
Extremely limited animal data suggest that the primaty target of inhalation exposure to 
N-nitrosodiphenylamine is the respiratory system. There may also be some immunological and neurological 
effects. 
No information was located regarding toxic effects in humans following acute, intermediate, or chronic oral 
exposure to N-nitrosodiphenylamine. Limited animal studies give data primarily on intermediate and 
chronic exposure. The target organ of N-nitrosodiphenylamine toxicity in rats, and possibly in mice, is the 
urinary bladder, although minor hepatic and ocular alterations have also been reported. 
Chronic studies have reported that tumors occurred in rats and mice following a lifetime exposure to 
N-nitrosodiphenylamine in the diet. At lower doses, tumors were not evident. IARC has concluded that 
no evaluation of the carcinogenicity of N-nitrosodiphenylamine to humans is currently possible, and there 
is limited evidence for the carcinogenicity of N-nitrosodiphenylamine in experimental animals (IARC 1982a; 
1587). Negative results have been found in in vivo tests and in vitro gene mutation and chromosome 
assays. However, there are conflicting results in in vitro human fibroblast DNA damage assays. 
No information was located regarding toxic effects in humans following acute, intermediate, or chronic 
dermal exposure to N-nitrosodiphenylamine. Animal studies of poor quality found that N-nitrosodiphenylamine 
can irritate the skin. 
No inhalation MRLs were derived because no human data and no reliable animal data exist. For the same 
reasons, no oral MRLs were derived for intermediate or acute exposure. No oral MRL was derived for 
chronic exposure because no human data exists and the only effects observed in a reliable animal study 
(epithelial hyperplasia and squamous metaplasia of the urinary bladder, seen in NCI 1979) were considered 
to be preneoplastic. No MRLs were derived for acute, intermediate, or chronic dermal exposure to 
Nnitrosodiphenylamine because appropriate MRL methodology has not been developed for this route. 
Death. Although there have been no deaths reported in humans from N-nitrosodiphenylamine exposure, 
animal data suggest that fatalities can occur at high doses. Rats have been shown to be more susceptible 
to N-nitrosodiphenylamine toxicity than mice. Chronic studies by NCI (1979) found decreased survival in 
mice exposed to 711 mg/kg and in rats exposed to 200 mg/kg. An oral rat LD50 of 3,000 mg/kg was 
reported by Druckrey et al. (1967). There were no studies regarding lethality following inhalation exposure, 
which is assumed to be a likely route of exposure in humans. 
Systemic Effects 
Only limited histopathological data from an oral chronic-duration animal study are available for respiratory, 
cardiovascular, gastrointestinal, hematological, and musculoskeletal effects (NCI 1979). No pathological 
changes related to treatment were found in tissues from these systems that were analyzed. The significance 
of exposure in humans cannot be determined from these data. 
    












Hepatic Effects.  Evidence suggests that N-nitrosodiphenylamine may cause slight, but not major, damage 
to the liver at high oral doses in animals. An intermediate-duration study revealed pigmentation of 
Kupffer’s cells in hepatic sinusoids in mice exposed to N-nitrosodiphenylamine in the diet. Electron 
microscopic examination revealed an increased number of smooth endoplasmic reticula distributed among 
glycogen granules, blebs, hypertrophy, and pleomorphism of the mitochondria in Swiss-Webster mice treated 
with N-nitrosodiphenylamine for 4 days (Nishie et al. 1972). These changes are believed to be 
representative of liver enzyme induction. Since there were no studies available to evaluate hepatotoxicity 
following inhalation exposure and there are no human data, judgments regarding the significance of these 
results for humans cannot be made. 
Renal Effects. The urinary bladder is considered the target organ of N-nitrosodiphenylamine toxicity in 
animals. However, no data are available regarding bladder toxicity in humans. Data regarding the effects 
of acute exposure are not available, but chronic studies have reported toxic effects in the bladder of 
N-nitrosodiphenylamine-treated animals. Epithelial hyperplasia and a small degree of squamous metaplasia 
were evident in a few rats fed 50 and 200 mg/kg for 100 weeks (NCI 1979). There was a high incidence, 
of submucosal inflammation, as well as a minimal incidence of epithelial hyperplasia, of the urinary bladder 
in mice receiving 130-2,600 mg/kg N-nitrosodiphenylamine in the diet (NCI 1979). There is no 
information to indicate whether adverse bladder effects would occur in humans after exposure to 
N-nitrosodiphenylamine. However, other nitrosamines have been shown to adversely affect the bladder, 
and there is evidence to suggest that bladder cancer rates are higher in the rubber industry (the main 
industry using N-nitrosodiphenylamine) than in the general population (Boyland et al. 1968; NCI 1979). ’ 
Dermal/Ocular Effects.  A chronic oral study reported grossly observable cornea1 opacity in 15 of 50 male 
rats exposed to 200 mg/kg and 16 of 50 female rats exposed to 50 mg/kg (Cardy et al. 1979; NCI 1979). 
There is no information on whether exposure to this chemical may produce similar effects in humans. 
People living near hazardous waste sites could be at risk if the water supply were contaminated. 
Other Systemic Effects. Decreases in body weight were observed in rats exposed to oral doses of 
N-nitrosodiphenylamine for intermediate and chronic durations, and in mice exposed chronically to the 
chemical (NCI 1979). The decrease was >l0% in rats exposed to levels of ≥200 mg/kg/day for 11 weeks, 
and the decrease was much more significant in females at 800 mg/kg/day (39% decrease relative to 
controls), the dose at which survival was also significantly decreased. The significance of body weight 
depression for humans cannot be determined from this study, and no additional data exist by which to 
assess the relevance to human health. 
Immunological Effects. Limited histopathological data from a chronic animal study do not show adverse 
immunological effects due to oral exposure to N-nitrosodiphenylamine (NCI 1979). The relevance to 
human exposure cannot be determined from these data. 
Neurological Effects. Limited histopathological data from a chronic animal study do not show adverse 
neurological effects due to oral exposure to N-nitrosodiphenylamine (NCI 1979). The relevance to human 
exposure cannot be determined from these data. 
Developmental Effects. No studies were located regarding developmental effects in humans or animals 
after inhalation, oral, or dermal exposure to N-nitrosodiphenylamine. Since no information is available, 









2. HEALTH EFFECTS 
Reproductive Effects. Limited histopathological data from a chronic animal study do not show adverse 
reproductive effects due to oral exposure to N-nitrosodiphenylamine (NCI 1979). The relevance to human 
exposure cannot be determined from these data. 
Genotoxic Effects.   No epidemiology or case studies were available for genotoxicity of N nitrosodiphenylamine 
in humans. The only human data regarding the genotoxic effects of this chemical come from in vitro assays for 
DNA damage and sister chromatid exchange. Human fibroblasts were used to test for DNA damage from 
metabolically activated N-nitrosodiphenylamine (Agrelo and Amos 1981; Martin and McDermid 1981; Snyder 
and Matheson 1985). Only one of the three studies produced a positive response (see Table 2-2). A positive but 
statistically insignificant response was noted for increased sister chromatid exchange frequency in human 
lymphocytes after exposure to activated N-nitrosodiphenylamine (Lindahl- Kiessling et al. 1989). It is difficult 
to draw conclusions for humans from these data. However, from these and other studies it appears that N-
nitrosodiphenylamine is not a human clastogen. 
In vivo animal studies involving mice and rats consistently show negative results for DNA damage, 
micronuclei, DNA synthesis inhibition, and abnormal sperm morphology (see Table 2-3). A recessive lethal 
study involving Drosophila melanogaster produced a negative result as well (Vogel et al. 1981). However, 
in a host-mediated assay, a positive response for DNA damage was observed in Escherichia coli that were 
injected along with N-nitrosodiphenylamine into the abdomina of male Drosophila melanogaster 
(Knasmuller et al. 1990). The most commonly tested route of exposure for these studies was 
intraperitoneal injection in mice (McFee et al. 1989; Salamone et al. 1981; Topham 1981; Tsuchimoto and 
Matter 19Sl). Oral exposure was tested in only three studies (Brambilla et al. 1987; Friedman and Staub 
1976; McFee et al. 1989). From this information, N-nitrosodiphenylamine does not appear to be genotoxic 
to intact animal systems. 
Data from in vitro studies using prokaryotic and eukaryotic organisms and cultured mammalian cells are 
presented in Table 2-3. The response has been negative for the majority of gene mutation studies. 
However, two Salmonella assays detected gene mutations after exposure to metabolically activated 
N-nitrosodiphenylamine (Khudoley et al. 1987; Zielenska and Guttenplan 1988). N-Nitrosodiphenylamine 
exhibited no effect on mitotic crossing-over and gene conversion in Saccharomvces cerevisiae (Jagannath 
et al. 1981; Kassinova et al. 1981; Sharp and Parry 1981a). Chromosomal aberration assays for Chinese 
hamster fibroblasts and Don cells were inconclusive (Abe and Sasaki 1977; Ishidate and Odashima 1977). 
Sister chromatid exchange was unaffected in hamster ovary cells (Evans and Mitchell 1981; Perry and 
Thomson 1981), but a positive response for sister chromatid exchange was noted in hamster Don cells after 
exposure to N-nitrosodiphenylamine that had not been metabolically activated (Abe and Sasaki 1977). 
Tests for DNA damage have produced mixed results among prokaryotes and fungi. Among mammalian 
hepatocytes, however, the results for DNA damage have been positive. As mentioned previously, only one 
study involving cultured human fibroblasts was positive for DNA damage (Snyder and Matheson 1985). 
Most of the positive in vitro responses occurred in cases where exogenous metabolic activation was 
involved. This suggests that if N-nitrosodiphenylamine has genotoxic potential, the potential may arise from 
its metabolites. In fact, many N-nitroso compounds are thought to exert their mutagenic and carcinogenic 
effects through intermediates derived from alpha-carbon hydroxylation; these intermediates can alkylate 
DNA (Magee et al. 1976; Preussman and Stewart 1984; Schut and Castonguay 1984). However, since 
N-nitrosodiphenylamine is not susceptible to alpha-carbon oxidation, it presumably exerts its action by some 
mechanism other than direct alkylation. Some researchers speculate that the carcinogenicity of 
N-nitrosodiphenylamine is due to transnitrosation with carcinogenic N-nitroso derivative(s) formation (NCI 


















the formation of nitrosamines by nitrosation of dietary amines. This theory is supported by a Salmonella 
Ames test in which N-nitrosodiphenylamine was found to be mutagenic in strains TA98 and TA100 only 
after it was nitrosated in vitro; significantly positive responses were observed in systems without activation 
(Crchelli cl al. 1984). Alternatively, transnitrosation could occur from N-nitrosodiphenylamine to another 
compound. Evidence exists for transnitrosation by N-nitrosodiphenylamine in vivo; transnitrosation from 
N-nitrosodiphenylamine to proline occurred in rats when the compounds were coadministered orally 
(Ohshima et al. 1982). The transnitrosation mechanism is consistent with the negative results obtained for 
N-nitrosodiphenylamine in assays for mutagenicity (with or without metabolic activationj and the positive 
results obtained in the NCI (1979) dietary-carcinogenesis study in rats. 
Cancer. The only neoplastic lesion shown to be significantly correlated with N-nitrosodiphenylamine 
csposure was an increase of bladder transitional cell carcinoma in rats (Cardy et al. 1979; NCI 1979). The 
difference was significant at only the higher of the two doses tested. Increases in other neoplastic lesions. 
including cancers of the integumentav system and liver, were found in orally exposed rats and mice (Cardy 
cl al. 1979); Innes et al. 1969; NCI 1968, 1979), but the increases were not statistically significant. Some 
early studies reported no treatment-related tumors in orally exposed rats (Argus and Hoch-Ligeti 1961; 
Druckrcy ct al. 1967); however, the bladder was not routinely examined in these studies. A nonsignificant 
increase in reticulum cell sarcomas was reported in 28-day-old mice subcutaneously injected with 
1.000 mgikg N-nitrosodiphenvlamine and observed for 18 months (Innes et al. 1969; NCI 1968). EPA has 
calculated a q1* of 4.92×10-3 (mg/kg/day)-1 based on the bladder cancer in rats. According to EPA’s 
Integrated Risk Information System (IRIS) database, N-nitrosodiphenylamine is a probable human 
carcinogen (class B2). According to IARC, N-nitrosodiphenylamine is a level 3 chemical, meaning there 
is not enough data to determine the potential carcinogenicity of this compound (IARC 1987). Given the 
equivocal nature of the data from most of these studies and the lack of information for humans, no 
statements regarding the possible carcinogenicity of N-nitrosodiphenylamine in humans can be made. 
2.5 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
heen classified as markers of exposure. markers of effect, and markers of susceptibility (NAS/NRC 1989). 
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself 
or substance-specific metabolites in readily obtainable body fluid(s) or excreta. However, several factors 
can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may 
be the result of exposures from more than one source. The substance being measured may be a metabolite 
of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several 
different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and 
environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites 
may have left the body by the time biologic samples can be taken. It may be difficult to identify 
individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., 
essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 
N -nitrosodiphenylamine are discussed in Section 2.5.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health impairment 
or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue 









dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), 
as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. 
Note that these markers are often not substance specific. They also may not be directly adverse, but can 
indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by 
N-nitrosodiphenylamine are discussed in Section 2.5.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic 
or other characteristic or a preexisting disease that results in an increase in absorbed dose, biologically 
effective dose, or target tissue response. If biomarkers of susceptibility exist, they are discussed in 
Section 2.7, “Populations That Are Unusually Susceptible.” 
2.5.1 Biomarkers Used to Identify or Quantify Exposure to N-Nitrosodiphenylamine 
N-Nitrosodiphenylamine can be detected and quantitated in the blood, serum, and urine of animals, with 
the lowest detection limits for serum (Pylypiw and Harrington 1981). Limited animal data suggest that 
suspected metabolites of N-nitrosodiphenylamine can also be detected in the urine. However, these 
methods do not appear to have been used to test humans for exposure. and no monitoring data for 
N-nitrosodiphenylamine were located. Therefore, no conclusion regarding the usefulness of these potential 
hiomarkers in humans can be made, although it is reasonable to assume that they can indicate exposure. 
There are no other known biomarkers of exposure to N-nitrosodiphenylamine. 
There are no data on how long N-nitrosodiphenylamine persists in the body of humans or animals. In one 
study, ninety-six hours after the administration of an oral dose, 30% of the dose had been eliminated in 
the urine (Appel et al. 1984). However, it is not known how much was eliminated in the feces or by other 
routes, and how much was retained in the body. No data are available regarding the exposure levels that 
would result in levels detectable in body fluids. 
2.5.2  Biomarkers Used to Characterize Effects Caused by N-Nitrosodiphenylamine 
Based on data in rats and mice, t,he target organ appears to be the urinary bladder. Observed effects 
consist of epithelial hyperplasia and squamous metaplasia of the bladder (NCI 1979). These effects were 
seen at the lowest dose tested (50 mg/kg/day), and the effect is only observable post-mortem. In addition, 
these effects can occur from other circumstances such as disease, exposure to drugs, and exposure to other 
chemicals, and are not unique to N-nitrosodiphenylamine. Therefore, they are not useful as specific 
hiomarkers of effect for N-nitrosodiphenylamine. There are so few data available on the chemical that it 
is difficult to associate specific symptoms with exposure to N-nitrosodiphenylamine. 
2.6  INTERACTIONS WITH OTHER CHEMICALS 
N-Nitrosodiphenylamine was mutagenic in strains TA98 and TA1535, but not TA100, in preincubation 
assays with rat liver S-Y fractions only in the presence of the comutagen norharman (9H-pyrido­
[3,4b]indole) (Nagao and Takahashi 1981; Wakabayashi et al. 1981, 1982). 
In mice treated with N-nitrosodiphenylamine prior to pentobarbital administration, pentobarbital sleeping 
time was significantly shortened compared to control mice given only the corn oil vehicle (Nishie et al. 








2.7  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceprible population will exhibit a different or enhanced response to N-nitrosodiphenylamine than will 
most persons exposed to the same level of N-nitrosodiphenylamine in the environment. Reasons include 
crenetic make-up, developmental stage, health and nutritional status. and chemical exposure history. These b 
parameters result in decreased function of the detoxification and excretory processes (mainly hepatic and 
renal) or the pre-existing compromised function of target organs. For these reasons we expect the elderly 
with declining organ function and the youngest of the population with immature and developing organs 
will generally be more vulnerable to toxic substances than healthy adults. Populations who are at greater 
risk due to their unusually high exposure are discussed in Section 5.6, “Populations With Potentially High 
Exposure.” 
It is difficult to determine persons with increased risk because there are limited data on the toxicity of 
N-nirrosodiphenylamine. People that have bladder dysfunction or disease may be more susceptible since 
rhe primary effect of N-nitrosodiphenylamine in animals is bladder cancer. 
The induction of the hepatic microsomal enzymes, such as the mixed function oxidases, by N-nitrosodiphenylamine 
may affect the metabolism of some drugs and alcohol. The efficacy of prescription drugs may be altered because of 
the increased rate of metabolism. 
2.8  METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to N-nitrosodiphenylamine. However, because some of the treatments discussed may be 
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
N-nitrosodiphenylamine. When specific exposures have occurred, poison control centers and medical 
toxicologists should be consulted for medical advice. 
2.8.1 Reducing Peak Absorption Following Exposure 
Human exposure to N-nitrosodiphenylamine may occur by inhalation, ingestion, or dermal contact. The 
major routes of exposure to N-nitrosodiphenylamine for individuals living near hazardous waste sites are 
inhalation of airborne dust particles or ingestion of contaminated water. There is little actual experience 
in treatment of persons exposed to this compound. However, general recommendations for reducing 
absorption of N-nitrosodiphenylamine following acute exposure include removal from the source of 
exposure. In the case of inhalation exposure, the patient is moved to fresh air. If the eyes are exposed, 
they are irrigated with copious amounts of water. If dermal contact has occurred, contaminated clothing 
is removed and the exposed area is thoroughly washed with soap and water (HSDB 1992). 
Following oral exposure, prevention of the absorption of N-nitrosodiphenylamine is imperative. The 
method used for reducing peak absorption is dependent on the amount ingested, the time since ingestion, 
and rhe patient’s condition. Emesis may be considered unless the patient is comatose, is convulsing, or 
has lost rhe gag reflex. Caution concerning the use of this method stems from the risk of aspiration of 
vomit into the lungs. Gastric lavage may be used as an alternative to emesis. Endotracheal intubation 
may be performed to reduce the risk of aspiration pneumonia. Administration of a charcoal slurry, 







2.8.2 Reducing Body Burden 
There are no data regarding methods to enhance elimination of N-nitrosodiphenylamine. As in methods 
used with other chemicals, hemodialysis might be useful following acute intoxication, but no data were 
located regarding this possibility. After a single oral dose of N-nitrosodiphenylamine, the maximum urinary 
excretion of its metabolites (nitrate and nitrite) was found within 24-48 hours. The metabolites of 
Nnitrosodiphenylamine have been associated with hepatic and renal toxicity. No information was located 
on the hioaccumulation of N-nitrosodiphenylamine or its metabolites. However, there are data that indicate 
N-nitrosodiphenylamine has a low potential for bioaccumulation, based on the log KOW (see Section 53.1). 
2.8.3 Interfering with the Mechanism of Action for Toxic Effects 
Based on a multicompartmental pharmacokinetic model, Kadlubar et al. (1991) predicted that DNA adduct 
formation by 4-aminohiphenyl in the bladder epithelial cells would decrease with increasing frequency of 
voiding. A similar situation may exist with N-nitrosodiphenylamine. Since this compound causes bladder 
cancer in rats (Cardy et al. 1979; NCI 1979), increased voiding frequency might similarly mitigate its effects. 
Like N-nitrosodiphenylamine, its metabolite diphenylamine has been associated with nephrotoxic effects. 
However, no information on the mechanism of action for nephrotoxicity of either chemical was located. 
Results from Wakabayashi et al. (1982) suggest that the carcinogenic effects of N-nitrosodiphenylamine may 
be due to interaction with other compounds. This study found that although N-nitrosodiphenylamine is 
not mutagenic in Salmonella tvphimurium TA98, it is mutagenic in the presence of norharman 
(β-carboline). Norharman has been found in a tobacco smoke, a tryptophan pyrolysate, and cooked foods. 
The effect was not due to transnitrosation, since a similar effect was seen with diphenylamine. However, 
other authors have suggested that transnitrosation of or by N-nitrosodiphenylamine could be mechanistically 
important. Since the mechanism of N-nitrosodiphenylamine carcinogenicity is unknown, no methods can 
be suggested for interfering with it. 
Since there is no evidence that N-nitrosodiphenylamine bioaccumulates, the best mitigation would be to 
reduce absorption. If the carcinogenic metabolite were identified, it would be possible to consider 
interfering with its generation. However the metabolite is not known, and the metabolic enzymes involved 
have not been identified. 
2.9  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of N-nitrosodiphenylamine is available. Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of N-nitrosodiphenylamine. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce or eliminate the uncertainties of human health assessment. This definition should not be 
interpreted to mean that all data needs discussed in this section must be filled. In the future, the 











2.9.1  Existing Information on Health Effects of N-Nitrosodiphenylamine 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
N-nitrosodiphenylamine are summarized in Figure 2-3. The purpose of this figure is to illustrate the 
existing information concerning the health effects of N-nitrosodiphenylamine. Each dot in the figure 
indicates that one or more studies provide information associated with that particular effect. The dot does 
not imply anything about the quality of the study or studies. Gaps in this figure should not he interpreted 
as “data needs” information (i.e., data gaps that must necessarily be filled). 
No human data were located for N-nitrosodiphenylamine. The animal data on this chemical are limited. 
Most of the studies investigate the potential carcinogenicity of N-nitrosodiphenylamine following oral 
exposure: however, one dermal study provides information on the toxicity and carcinogenicity of the 
compound by this route. Oral data on toxicity come primarily from a carcinogenicity study in rats and 
mice conducted by the National Cancer Institute (NCI). Most of the data are based on extensive 
histological examination of tissues from exposed animals. although body weight and survival information 
were also provided. Several studies on the oral carcinogenicity of the chemical were located. 
2.9.2  Identification of Data Needs 
Acute-Duration Exposure.   No cases of accidental or intentional poisonings were available to evaluate 
acute exposure in humans. There was a paucity of animal data, especially in animals exposed via inhalation 
or dcrmal routes. Enzyme induction in the liver was observed in mice receiving N-nitrosodiphenylamine 
by oral gavage for 4 days (Nishie et al. 1972). An acute oral LD50 was established for rats, but no 
inhalation LC50 or dermal LD50 studies were available (Druckrey et al. 1967). Insufficient information 
prevented the derivation of an acute-duration oral MRL. Pharmacokinetic data were not available to 
support the identification of target organs across routes of exposure. Inhalation and dermal data in 
mammalian species would be useful for determining possible effects of acute exposures in the population. 
The potential exists for the occurrence of acute exposure to N-nitrosodiphenylamine in populations near 
hazardous waste sites and accidental spills. 
Intermediate-Duration Exposuye. There is no information on repeated exposure to N-nitrosodiphenylamine 
in humans. Rats showed body weight depression in an 8-11-week feeding study (NCI 1979). A 
low incidence of pigmentation of Kupffer’s cells occurred in mice fed a diet containing a high concentration 
of N-nitrosodiphenylamine, but the effect was not considered adverse (NCI 1979). Well-conducted 
intermediate-duration inhalation and dermal studies would be useful in determining whether adverse effects 
occur via these exposure routes. Additional intermediate-duration oral studies that identify target organs 
and use several different animal species would be very helpful in determining potential adverse health 
effects in humans. 
Chronic-Duration Exposure and Cancer. Chronic oral studies in rats have shown decreased body weight 
and bladder effects in the form of squamous metaplasia and submucosal inflammation (Cardy et al. 1979; 
NCI 1979). The only other noncancer health effect of N-nitrosodiphenylamine was cornea1 opacity in the 
high-dose male rats and low-dose female rats (Cardy et al. 1979; NCI 1979). These data indicate that the 
bladder is the target for chronic oral exposure to this chemical. A chronic oral MRL was not derived for 
N-nitrosodiphenylamine because the bladder effects were considered preneoplastic. Long-term animal 
studies via the inhalation and dermal routes would be valuable for determining whether similar chronic 
effects would occur, and if exposures via these routes could cause toxicity in populations exposed to 














No information was available on the carcinogenic potential of N-nitrosodiphenylamine in humans. 
Although contlicting cancer results have been seen in chronic bioassay there are enough oral exposure 
data to indicate that this chemical is carcinogenic in rats, primarily in the bladder. The only pertinent 
study of carcinogenicity following dermal exposure in mice lacked information that is critical for a thorough 
evaluation. The histological examinations were limited and no controls were used. Kinetic data suggest 
that N-nitrosodiphenylamine may be absorbed through the skin (Iversen 1980). More data concerning the 
actual risk of cancer from dermal exposure are needed since a possible route of exposure to humans is 
from contaminated soil. 
Genotoxicity. Data from in vitro assays suggest that N-nitrosodiphenylamine and/or one or more of its 
metabolites may damage DNA in mammalian liver cells (McQueen et al. 1983). However, in vivo studies 
of this type are lacking. In addition, oral and perhaps even dermal exposure in vivo studies in animals 
would he useful since these are the routes of exposure pertinent to humans. Additional studies that 
investigate chromosomeichromatid effects in different animals and tissue/organ systems would help confirm 
or refute the inconclusive evidence (Abe and Sasaki 1977; Ishidate and Odashima 1977; McFee et al. 198’); 
Salamone et al. 1981) regarding this compound’s clastogenicity. Genotoxicity assays in humans exposed 
to N-nitrosodiphenylamine would help to determine this chemical’s status as a human genotoxin following 
in vivo exposure. Additional data on the metabolism of this compound would be very useful in assessing 
the inconsistencies of the available information. 
Reproductive Toxicity. No human data and limited animal data were available regarding reproductive 
effects of N-nitrosodiphenylamine. Given the lack of reproductive information, any studies investigating 
adverse reproductive effects using different species and different routes of administration would be useful. 
Reproductive organ pathology could be examined in a 90-day study recommended under intermediateduration 
exposure. 
Developmental Toxicity. There were no studies evaluating developmental effects in humans or animals. 
Data regarding potential developmental effects would be useful. Information is also lacking on the kinetics 
of N-nitrosodiphenylamine, such as its distribution and whether it is likely to cross the placenta. 
Immunotoxicity. No studies were found that specifically investigated the immunotoxicity of N-
nitrosodiphenylamine in either humans or animals. Studies specifically addressing the immune system responses in 
mammalian species would be valuable in assessing possible long-term health effects in humans that might retlect 
subtle changes in the immune system. Dermal studies may also provide useful information on the potential for 
allergic responses since skin contact by humans can occur in the workplace and via soil and water near hazardous 
waste sites. 
Neurotoxicity. There were no human data and limited animal data evaluating the neurotoxicity of 
N-nitrosodiphenylamine. Given the lack of any information regarding neurotoxicity and the paucity of data 
concerning the mechanism of action of N-nitrosodiphenylamine, well-conducted acute, intermediate, and 
chronic studies across all exposure routes investigating neurological effects of N-nitrosodiphenylamine 
exposure would be useful. 
Epidemiological and Human Dosimetry Studies. There are no epidemiological studies available on 
N-nitrosodiphenylamine. Populations that may potentially be exposed to N-nitrosodiphenylamine would 
include workers in the rubber industry, those residing near hazardous waste sites, or workers involved in 
the cleaN-up of wastes. Rubber workers in cohort studies could be used as a potentially exposed 









air space would make quantifying this relationship difficult. This type of epidemiological study may help 
determine whether bladder toxicity may occur in humans as in animals. 
Biomarkers of Exposure and Effect.   Currently. there are no hiomarkers identified for human exposure 
to N-nitrosodiphenylamine. The chemical and some of its metabolites have been measured in the blood. 
serum. and urine of animals (Pylypiw and Harrington 1981). Monitoring data in humans with suspected 
occupational exposure to N-nitrosodiphenylamine would be useful. 
Currently. there are no human hiomarkers of effect identified for N-nitrosodiphenylamine. There are so 
few data available on the chemical that it is difficult to associate specific symptoms with exposure to 
N-nitrosodiphenylamine. The determination of the target organ in humans would be valuable for 
identifying possible effects to monitor in populations with high risk of exposure to the chemical, such as 
workers in the rubber industry. Furthermore. animal and epidemiological studies that correlate adverse 
health effects with levels in tissues would help researchers to devise more sensitive and more specific 
biomarkcrs of disease. 
Absorption, Distribution, Metabolism, and Excretion. There was no information available on relative 
rates and extent of absorption, distribution, metabolism. and excretion for inhalation, oral, or dermal 
exposure in humans or animals. Although there are no quantitative data on absorption, animal studies 
gave indirect evidence that N-nitrosodiphenvlamine was absorbed following administration of a single oral 
&se (Appel et al. L1984; Tatsumi et al. 1983) and during chronic oral exposure (Cardy et al. 1979; NCI 
1979). Absorption rate data for all three exposure routes would be useful in eslimating absorption 
characteristics in humans. 
No studies on the distribution pattern and rates of N-nitrosodiphenylamine were available for humans or 
animals. Chronic oral studies have reported alterations in specific organs in animals (Cardy et al. 1979; 
NCI 1979); however, N-nitrosodiphcnylamine levels in these tissues were not provided. Additional studies 
on distribution would assist in the evaluation of target organ toxicity of N-nitrosodiphenylamine. 
Metabolism of N-nitrosodiphenylamine was studied in rats (Appel et al. 1984) and guinea pigs (Tatsumi 
et al. 1983) exposed to a single oral dose. No inhalation or dermal studies were available. Additional 
studies are needed to assess whether differences in rate and extent of metabolism exist across the three 
routes of exposure and to predict the metabolism pattern of the chemical in humans. 
No human data and limited animal data were available on excretion. Rapid excretion occurs in rats after 
acute oral exposure (Appel et al. 1984). Studies on excretion following exposure via all routes would be 
useful for determining the variation in elimination pattern with route, and also the variation in excretion 
among species. 
Comparative Toxicokinetics.   No toxicokinetic information was available for humans. Pharmacokinetic 
data in animals, which could be used in the understanding of species differences in sensitivity and 
mechanism of toxicity to this chemical, are very limited (Appel et al. 1984; Atawodi and Maduagwu 1990; 
Ohshima ct al. 1982). Additional toxicokinetic studies in a variety of species would be useful indetermining the best 
animal model for evaluating N-nitrosodiphenylamine pharmacokinetic characteristics in humans. More 
toxicokinetic data would be helpful in assessing the potential for long-term health effects 
following chronic exposures, which are most likely to occur in residents living near hazardous waste sites. 
Mitigation of Effects.   Neither the mechanism of absorption of N-nitrosodiphenylamine, nor the 
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that orally administered N-nitrosodiphenylamine is absorbed (Appel et al. 1984; Cardy et al. 1979; NCI 
1979; Tatsumi et al. 1983). Information regarding these mechanisms would be useful in developing 
methods to reduce peak absorption. There are no established methods for reducing the body burden of 
this compound or any toxic metabolite(s), but the existing data suggest rhat N-nitrosodiphenylamine has 
a low potential for bioaccumulation (see Section 5.3.1). There is little actual experience in treating persons 
exposed to N-nitrosodiphenylamine. The mechanism of toxic action is not known, although possible 
carcinogenic mechanisms have been proposed (NCI 1979, Preussmann and Stewart 1984, Raineri et al. 
1981; Wakabayashi et al. 1982). Information regarding the nephrotoxic and possible carcinogenic 
mechanisms of N-nitrosodiphenylamine would be useful in developing methods to block its toxic effects. 
2.9.3 On-going Studies 
No on-going studies were located for N-nitrosodiphenylamine. 
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3. CHEMICAL AND PHYSICAL INFORMATION 
3.1 CHEMICAL IDENTITY 
The chemical identity of N-nitrosodiphenylamine is shown in Table 3-l. 
3.2  PHYSICAL AND CHEMICAL PROPERTIES 









4. PRODUCTION, IMPORT, USE, AND DISPOSAL 
4.1  PRODUCTION 
N-Nitrosodiphenylamine is not known to occur naturally in the environment (IARC 1982a). However, 
there is evidence to indicate that microorganisms produce the chemical under laboratory conditions 
(Ayanaba and Alexander 1973). It is possible that this may take place under environmental conditions also. 
N-Nitrosodiphenylamine has been produced by reacting diphenylamine and sodium nitrite in water that has 
been acidified with sulfuric acid (NIOSH 1983). The N-nitrosodiphenylamine is then separated from the 
aqueous layer, drained, dried on hot rollers, and packed as the final product into drums. 
N-Nitrosodiphenylamine had been produced commercially in the United States since 1945 (IARC 1982a). 
U.S. production volumes peaked in 1974 at 3.2 million pounds and gradually declined to 0.4 million pounds 
in 1980. The decline in production was due to the availability of new and more efficient chemicals for 
its applications in the rubber-processing industry (Taylor 1982). Production volumes are not available after 
1980 (USITC 1985, 1986, 1987, 1988). 
According to the Toxics Release Inventory (TRI), the two facilities in the United States that manufactured 
or processed N-nitrosodiphenylamine in 1988 were Arkansas Eastman Company (Batesville, Arkansas) and 
Uniroyal Chemical Company, Inc. (Geismar, Louisiana) (see Table 4-l) (TRI88 1990). The data listed in 
the TRI should he used with caution since only certain types of facilities are required to report. This is 
not an exhaustive list. In 1990, however, Uniroyal Chemical Company, Inc., was reportedly the only facility 
in the United States producing N-nitrosodiphenylamine (SRI 1990). 
4.2  IMPORT/EXPORT 
Imports of N-nitrosodiphenylamine through principal U.S. customs districts increased from 52,000 pounds 
in 1977 to 110,000 pounds in 1982 (USITC 1978a, 1983). Current import and export data for 
N-nitrosodiphenylamine are not available. 
4.3 USE 
N-Nitrosodiphenylamine was primarily used as a retardant in the rubber-processing industry (HSDB 1990). 
Retardants are chemicals that prevent the premature vulcanization of rubber compounds during certain 
rubber-processing steps such as mixing and calendaring. N-Nitrosodiphenylamine was generally used with 
the sulfcmamide accelerators in tire compounds. The use of N-nitrosodiphenylamine as a retardant had 
the following undesirable side effects: gaseous decomposition products of N-nitrosodiphenylamine during 
vulcanization cause porosity in thick cross-section extrusions; N-nitrosodiphenylamine is a nitrosating agent 
of secondary amines, which are suspected to be animal carcinogens: it is slightly staining; and it is not 
efficient in the presence of alkyl-atyl or dialkyl-substituted p-phenylenediamine antidegradants (Taylor 1982). 
N-Nitrosodiphenylamine was also used as an intermediate in the manufacture of p-nitrosodiphenylamine. 
p-Nirrosodiphenylamine can be reduced to N-phenyl-p-phenylenediamine, which is also a rubber-processing 
chemical and an intermediate in the production of other rubber-processing chemicals (OHM/TADS 1990). 
4.4 DISPOSAL 
Product residues and sorbent media containing N-nitrosodiphenylamine can be packaged in 17H epoxy-lined 
drums and disposed of at an EPA-approved site. The compound can be destroyed by high-temperature 
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5. POTENTIAL FOR HUMAN EXPOSURE 
5.1 OVERVIEW 
N-Nitrosodiphenylamine is used as a vulcanization retardant in rubber compounds used to make tires. 
There is some evidence to suggest it is produced by microorganisms in the environment. In 1988 it was 
being produced and used by two manufacturers in the United States (TRIM 1990). Currently, only one 
manufacturer in the United States produces and uses N-nitrosodiphenylamine (SRI 1090). Releases to the 
environment occur from effluent discharges generated from its production and use and from leachate at 
hazardous waste sites. 
N-Nitrosodiphenylamine exists in the vapor phase in the atmosphere. It is subject to volatilization from 
water. Significant leaching is not expected to occur because of its low soil mobility. In the aquatic 
environment, N-nitrosodiphenylamine partitions from the water column to sediments and suspended 
parriculate organic matter. It is subject fo photolysis and biodegradation. Biomagnification in the aquatic 
food chain is not considered to he a major environmental fate process since N-nitrosodiphenylamine .has 
a low potential for bioaccumulation in aquatic organisms. 
The general population of the United States does not appear to be exposed to any background levels of 
N-nitrosodiphenylamine. However, no studies investigating the concentrations of N-nitrosodiphenylamine 
in drinking water, foods, or ambient air were located. 
N-Nitrosodiphenylamine has been identified in 172 of the 1,300 NPL hazardous waste sites (HAZDAT 
1992). The frequency of these sites within the United States can be seen in Figure 5-1. 
5.2 RELEASES TO THE ENVIRONMENT 
5.2.1  Air 
N-Nitrosodiphenylamine may he released to the atmosphere from sewage sludge incinerators (Gerstle 1988) 
or from hazardous waste sites. Release of N-nitrosodiphenylamine to the environment can occur from 
effluent discharges generated from its production and use. 
5.2.2 Water 
N-Nitrosodiphenylamine may be released in industrial waste water (Rhoades et al. 1980). There is also 
evidence suggesting that some microorganisms produce N-nitrosodiphenylamine from diphenylamine and 
nitrare or nitrite in the environment (Ayanaba and Alexander 1973). Although this has only been shown 
for pure cultures under laboratory conditions, it may be a natural source of N-nitrosodiphenylamine in the 
environment. N-Nitrosodiphenylamine was detected in an estimated 3.6% of the groundwater and 0.71% 
of the surface water samples analyzed at NPL sites included in EPA’s Contract Laboratory Program (CLP). 
Estimated geometric mean concentrations of 7.8 ppb in groundwater and 9.4 ppb in surface water were 
reported in the positive samples (CLPSD 1989). Note that the information used from the CLP Statistical 
Database (CLPSD) includes data from NPL sites only. According to the Toxics Release Inventory (TRI), 
an estimated total of at least 27 pounds of N-nitrosodiphenylamine was released to water from 
manufacturing and processing facilities in the United States in 1988 (TRI88 1990). Table 5-1 lists the 
amounts released from these facilities. The data should be used with caution since only certain types of 
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5.2.3  Soil 
N-Nitrosodiphenylamine potentially can be released to soil from leachate at hazardous waste sites, 
underground injection wells, or off-site waste transfer (TRISS 1990). There is also evidence suggesting it 
might he produced by some microorganisms under certain environmental conditions (Ayanaba and 
Alexander 1973). However, N-nitrosodiphenylamine was not detected in soil samples at any of the NPL 
sites included in the CLPSD (CLPSD 1989). 
5.3  ENVIRONMENTAL FATE 
5.3.1  Transport and Partitioning 
N-Nitrosodiphenylamine has a vapor pressure of 0.1 mmHg at 25°C (HSDB 1990). It should exist almost 
entirely in the vapor phase in the atmosphere (Eisenreich et al. 1981). 
N-Nitrosodiphenylamine is soluble in water (40 mg/L) (EPA 1982a). The Henry’s law constant for 
N-nitrosodiphenylamine (6.6×10-4 atm-m3/mol) (EPA 1982a) indicates that volatilization from water will 
he 3 slow but significant transport process (Lyman et al. 1982). 
The soil sorption coefficient (KOC) for N-nitrosodiphenylamine was estimated to range from 830 to 
1,830 (Lyman et al. 1982). This KOC range is indicative of low mobility in soil; therefore, significant 
leaching is not expected to occur in most types of soil (Swann et al. 1983). In the aquatic environment, 
substantial partitioning from the water column to sediment and suspended particulate organic matter may 
occur. 
The logarithm of N-octanollwater partition coefficient (log KOW) is a useful preliminary indicator of 
potential bioaccumulation of a compound. The log KOW for N-nitrosodiphenylamine was estimated to range 
from 2.57 to 3.13, indicating a low potential for bioaccumulation (Banerjee et al. 1980; Barrows et al. 
1980). An experimental bioconcentration factor of 217 was determined for N-nitrosodiphenylamine based 
on a continuous 14day exposure study of bluegill sunfish with a mean N-nitrosodiphenylamine water 
concentration of 9.21 ppb (Barrows et al. 1980). The half-life of IV-nitrosodiphenylamine in the fish was 
found to be less than I day when the fish were placed in pollutant-free water after the exposure period. 
The relatively low experimental bioconcentration potential and short half-life of N-nitrosodiphenylamine 
indicate that biomagnification in the aquatic food chain is not a major environmental fate process (Barrows 
et al. 1980). 
5.3.2  Transformation and Degradation 
5.3.2.1 Air 
N-Nitrosodiphenylamine absorbs sunlight, suggesting a potential for direct photolysis in a sunlit 
environment (EPA 1979). Irradiation experiments using a benzene solution of N-nitrosodiphenylamine have 
shown that N-nitrosodiphenylamine is photodecomposed at sunlight wavelengths (Sharma et al. 1986). The 
rate at which photolysis occurs was not determined. N-Nitrosodiphenylamine also reacts with hydroxyl 
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5.3.2.2   Water 
The major environmental fate process for N-nitrosodiphenylamine in water is biodegradation. A staticculture 
flask-screening biodegradability test was performed using domestic waste water as the microbial 
inoculum and 5 and 10 ppm of N-nitrosodiphenylamine as the test compound (Tabak et al. 1981). At the 
end of 7 days, 87% degradation was achieved in the original culture dosed with 5 ppm, and 47% 
degradation was achieved in the original culture dosed with 11) ppm. After the second 7-day incubation 
period, 100%, degradation was achieved in the first subculture dosed with 5 ppm, while 63% degradation 
was achieved in the first subculture dosed with 10 ppm. After the fourth 7-day incubation period, 98% 
degradation was achieved by the third subculture dosed with 20 ppm. These results showed that N-
nitrosodiphenylamine was degradable, with rapid microbial adaptation at concentrations of 5 ppm and with more 
gradual microbial adaptation at concentrations of 10 ppm (Tabak et al. 1981). No studies were located 
regarding hydrolysis and oxidation of N-nitrosodiphenylamine. 
5.3.2.3  Soil 
Biodegradation is the major environmental fate process for N-nitrosodiphenylamine in soil. In laboratory 
tests using a sandy loam soil, 68% of added N-nitrosodiphenylamine was degraded after 30 days of 
incubation, but amending the soil with wheat straw (to increase microbial activity) resulted in complete 
disappearance of added N-nitrosodiphenylamine in 10 days (Mallik and Tesfai 1981). 
5.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
5.4.1  Air 
No data were located regarding the levels of N-nitrosodiphenylamine in air. 
5.4.2  Water 
No data were located regarding the levels of N-nitrosodiphenylamine in drinking water. Only one positive 
detection was found for ambient surface waters. N-Nitrosodiphenylamine was detected (no concentration 
reported) in the Cuyahoga River, which feeds Lake Erie (Great Lakes Water Quality Board 1983). 
5.4.3  Soil 
N-Nitrosodiphenylamine was measured at a concentration of 47 mg/kg (47,000 ppb) in a soil sample 
collected in 1978 near a manufacturing facility (NIOSH 1983). It has also been detected (no concentration 
reported) in the soil-sediment-water complex of the Love Canal near Niagara Falls, New York (Hauser and 
Bromberg 1982). 
5.4.4  Other Environmental Media 
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5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population does not appear to he exposed to any background levels of N-nitrosodiphenylamine. 
No data were located regarding levels of N-nitrosodiphenylamine in air, drinking water, or foods. 
The National Occupational Exposure Survey (NOES), conducted by NIOSH from 1981 to 1983 estimated 
that 1,093 workers employed at 137 plants were potentially exposed to N-nitrosodiphenylamine in the 
United States (NOES 1990). The NOES database does not contain information on the frequency, 
concentration. or duration of exposure to N-nitrosodiphenylamine. The survey provides only estimates of 
workers potentially exposed to chemicals in the workplace. 
N-Nitrosodiphenylamine was detected in the workplace air of an Ohio tire chemical factory in the spring 
of 1978. The concentrations of N-nitrosodiphenylamine ranged from 0 to 47 µg/m3 (0-6 ppb) (Fajen et 
al. 1979. 1980). A scraping from a staircase in the factory contained 15,000 ppm of N-nitrosodiphenylamine. 
Additional monitoring conducted in Ohio during the spring of 1978 found no detectable levels of 
N-nitrosodiphenylamine in the workplace air of an industrial rubber products factory, an aircraft tire 
factory, a synthetic rubber and latex factory, and three tire plants (Fajen et al. 1979, 1980). 
Levels of N-nitrosodiphenylamine ranging from not detectable to 12.35 µg/m3 (1.5 ppb) in workplace air 
samples were detected at a Kelly-Springfield tire plant in 1979 in the United States (NIOSH 1984). Levels 
ranging from below detectable limits (5 ng per sample) to 160 ng/m3(0.02 ppb) were detected in the 
breathing zone of curing press operators at a Uniroyal plant in Mishawaka, Indiana (NIOSH 1982). 
5.6  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers involved in the production and use of N-nitrosodiphenylamine may constitute a group at risk 
hecause of the potential for occupational exposure. Persons living near a production facility or a hazardous 
waste site containing N-nitrosodiphenylamine may have a higher risk of exposure to N-nitrosodiphenylamine 
resulting from contact with contaminated air, drinking water, or soil. If microorganisms are found to 
nitrosate diphenylamine in situ, then workers exposed to this chemical may be at higher risk of 
N-nitrosodiphenylamine exposure. Persons living near facilities producing, or waste sites containing, 
diphenylamine might also he at increased risk of exposure to N-nitrosodiphenylamine via microbial 
production of the chemical. 
5.7  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of N-nitrosodiphenylamine is available. Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine such 
health effects) of N-nitrosodiphenylamine. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce or eliminate the uncertainties of human health assessment. This definition should not be 
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identified data needs will he evaluated and prioritized. and a substance-specific research agenda will be 
proposed. 
5.7.1 Identification of Data Needs 
Physical and Chemical Properties.   The physical and chemical properties of N-nitrosodiphenylamine are 
sufficiently well defined to allow assessments of the environmental fate of the compound to be made. No 
additional information is needed. 
Production, Import/Export, Use, and Release and Disposal.   N-Nitrosodiphenylamine is currently 
produced and used by one manufacturer in the United States (SRI 1990). The general population does 
not appear to be exposed to any background levels. However, the available data do not permit a confident 
assessment of the background levels in air, drinking water, or foods. Disposal methods are well 
documented in the literature (HSDB 1990). More information on current production would be useful in 
estimating potential exposure to N-nitrosodiphenylamine. Further research on the possible production of 
N-nitrosodiphenylamine from diphenylamine by microorganisms would be useful in determining the 
potential for environmental contamination from this source. 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 
11023, industries are required to submit chemical release and off-site transfer information to the EPA. 
The Toxics Release Inventory (TRI), which contains this information for 1988, became available in May 
of 1990. This database will be updated yearly and should provide a list of industrial production facilities 
and emissions. 
Environmental Fate. N-Nitrosodiphenylamine is transported and partitioned in the air, water, and soil. 
It will sorb to soil and sediment (Swann et al. 1983). It is subject to photolysis in air and biodegradation 
in water and soil (EPA 1979; Sharma et al. 1986). Additional information regarding hydrolysis and 
oxidation and the half-lives for these processes would be helpful in determining the persistence of 
N-nitrosodiphenylamine at hazardous waste sites or at production sites where past levels were, or current 
levels might be. high. 
Bioavailability from Environmental Media. Limited available pharmacokinetic data in animals indicate 
that N-nitrosodiphenylamine is absorbed following oral exposure (Appel et al. 1984; Cardy et al. 1979; NCI 
1979 Tatsumi et al. 1983). Additional information on the absorption of this compound by these routes 
would be useful in evaluating the importance of the various routes of exposure to populations living in 
the vicinity of hazardous waste sites or near a production facility. 
Food Chain Bioaccumulation. N-Nitrosodiphenylamine is bioconcentrated in aquatic organisms to a 
limited extent (Barrows et al. 1980). Biomagnification in the aquatic food chain is not a major 
environmental fate process (Barrows et al. 1980). No data were located regarding bioaccumulation in 
terrestrial organisms. Since N-nitrosodiphenylamine might be found in soil under certain conditions, 
additional information would be helpful in determining the potential for biomagnification in the terrestrial 
food chain. 
Exposure Levels in Environmental Media. Current monitoring data were not located regarding levels 
of N-nitrosodiphenylamine in air. water, soil, or food. This information would be useful in determining 
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would also aid in determining if contamination due to production of N-nitrosodiphenylamine by 
microorganisms is of environmental concern. 
Exposure Levels in Humans. N-Nitrosodiphenylamine has been detected in the blood and urine of 
experimental animals (Pylypiw and Harrington 1981); however, there are no monitoring studies of human 
populations. Current human studies that monitor N-nitrosodiphenylamine in these fluids would be helpful 
in assessing the potential exposure of individuals who might be exposed through their work or of 
populations living in the vicinity of a production facility or a hazardous waste site. 
Exposure Registries.   No exposure registries for N-nitrosodiphenylamine were located. This substance 
is not currently one of the compounds for which a subregistry has been established in the National 
Exposure Registry. The substance will he considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
the exposure to this substance. 
5.7.2 On-going Studies 
No on-going studies were located for N-nitrosodiphenylamine. 
 
 




     
 
      
  
  





6. ANALYTlCAL METHODS 
The purpose of this chapter is to describe the analytical methods that are available for detecting and/or 
measuring and monitoring N-nitrosodiphenylamine in environmental media and in biological samples. The 
intent is not to provide an exhaustive list of analytical methods that could be used to detect and quantify 
N-nitrosodiphenylamine. Rather, the intention is to identify well-established methods that are used as the 
standard methods of analysis. Many of the analytical methods used to detect N-nitrosodiphenylamine in 
environmental samples are the methods approved by federal organizations such as EPA and the National 
Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those 
that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the 
American Public Health Association (APHA). Additionally, analytical methods are. included that refine 
previously used methods to obtain lower detection limits, and/or to improve accuracy and precision. 
6.1  BIOLOGICAL MATERIALS 
Analyrical methods exist for measuring N-nitrosodiphenylamine and its metabolites in the serum, blood, 
and urine of animals. However, because the data are very limited, a comparison of the methods cannot 
he made. The methods used are differential pulse polarography (DPP), thermal energy analyzer (TEA) 
(Pylypiw and Harrington 1981), high-performance liquid chromatography (HPLC) combined with detection 
by ultraviolet (UV) or UV-visible (UV-VIS) detection, or gas chromatography (GC) with detection by mass 
spectrometry (MS) (Appel et al. 1984; Tatsumi et al. 1983). Preparation steps for DPP and TEA include 
the addition of a buffer to the sample, which is then passed-through a Sep-Pac cartridge. The cartridge 
is washed with methanol (for DPP) or methylene chloride [for TEA), diluted with a buffer, concentrated 
under nitrogen (for TEA), and analyzed by DPP or TEA. Results were included only for N-nitroso­
N-methylaniline. The authors stated that results for N-nitrosodiphenylamine were comparable (Pylypiw and 
Harrington 1981). Detection limits obtained using DPP analysis for blood, serum, and urine were 0.5, 0.05, 
and 0.1 ppm, respectively. Recovery was good for all sample types, ranging from 85% to 101%; precision 
was excellent (<5%). Better sensitivity was obtained using TEA rather than the DPP. Detection limits 
obtained using TEA analysis for blood and serum were both 0.01 ppm. Recovery was good for both 
sample types, ranging from 82% to 96%; precision was excellent (<3%) (Pylypiw and Harrington 1981). 
No information was given on sensitivity, precision, or recovery using HPLC/UV, HPLC/UV-VIS, or GC/MS 
(Appel et al. 1984; Tatsumi et al. 1983). Table 6-1 gives a summary of the methods available for analyzing 
for N-nitrosodiphenylamine in biological materials. 
6.2 ENVIRONMENTAL SAMPLES 
Methods exist for measuring N-nitrosodiphenylamine in air, water, soil, and foods. The most common 
methods used are GC and HPLC combined with detection by TEA, flame-ionization detector (FID), or 
MS. Methods for analyzing for N-nitrosodiphenylamine in environmental samples are summarized in 
Table 6-2. 
N-Nitrosodiphenylamine is measured in air samples using GC/TEA and HPLC/TEA (NIOSH 1983). Air 
samples are collected with a ThermoSorb/N air sampling cartridge designed specifically for collection of 
airborne N-nitrosamines. A polar solvent (acetone, methanol, or methanol/dichloromethane) is then 
backflushed through the cartridge. The eluate is examined using GC/TEA and HPLC/TEA. The TEA has 
been specifically designed for the detection of N-nitroso compounds in the ppb range. TEA is not totally 
specific for N-nitroso compounds. Additional confirmation of positive results can be obtained by the use 
of HPLC/TEA. Specific sensitivity, recovery, and precision data were not reported. A group in 










column for collecting the sample and eluting with ethanol (Mejstrik et al. 1989). Precision and sensitivity 
were not reported, and experimental details were limited. 
N-Nitrosodiphenylamine is measured in water samples using GC/TEA, HPLCTEA, GC/FID, and highresolution 
gas chromatography (HRGC)/MS (Eichelberger et al. 1983; NIOSH 1983; Rhoades et al. 1980). 
Sample preparation steps involve extraction with methylene chloride, column clean-up with Florisil or 
Alumina, drying over sodium sulfate, and concentration in a Kuderna-Danish evaporator with solvent 
exchange to methanol. N-Nitrosodiphenylamine decomposes thermally in the hot gas chromatograph 
injection port to nitric oxide and diphenylamine and is measured as diphenylamine. Therefore, this 
compound cannot be accurately measured in a sample unless it is first separated from diphenylamine prior 
to GC. Florisileor Alumina column clean-up is usually employed for this separation (Eichelberger et 
al. 1983; Rhoades et al. 1980). Average recovery using GCTEA without Alumina column clean-up was 
86% while average recovery using GC/FID with Alumina column clean-up was 98%. Sensitivity was not 
reported (Rhoades et al. 1980). Recovery using GC/MS was 68%. Greater accuracy was obtained using 
HRGCMS (89%). Precision for both of these methods was adequate (13-14%). Sensitivity was not 
reported (Eichelberger et al. 1983). 
N-Nitrosodiphenylamine can be measured in soil using GC/TEA and HPLC/TEA (NIOSH 1983). Sample 
preparation involves extraction with an appropriate solvent and concentration. Precision, accuracy, and 
sensitivity for these methods were not reported. 
N-Nitrosodiphenylamine has been measured in foods using HPLC/TEA (Fine et al. 1976). Preparation 
steps for liquor samples involve extraction with dichloromethane, drying over sodium sulfate, concentration 
under a vacuum, and redissolving in dichloromethane. Recovery for this method is fair (60%). Sensitivity 
and precision were not reported. 
6.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of N-nitrosodiphenylamine is available. Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine such 
health effects) of N-nitrosodiphenylamine. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA They are defined as substance-specific informational needs that if met would 
reduce or eliminate the uncertainties of human health assessment. This definition should not be 
interpreted to mean that all data needs discussed in this section must be filled. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be 
proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.   No human studies were located 
regarding methods for determining levels of the compound in blood, serum, or urine. Animal data on the 
determination of N-nitrosodiphenylamine and its metabolites in these media are very limited (Appel et al. 






Harrington 1981). More information on the sensitivity, accuracy, and precision obtained for these methods 
is needed to evaluate the value of using levels of N-nitrosodiphenylamine as an indicator of exposure. The 
lack of human data for evaluation of these methods makes it difficult to assess whether these methods are 
sensitive for measuring background levels in the population and levels at which health effects might occur. 
Currently, no hiomarkers of effect have been identified for N-nitrosodiphenylamine. 
Methods for Determining Parent Compounds and Degradation Products in Environmental Media. 
Data on the methods used for determining N-nitrosodiphenylamine in air (Mejstrik et al. 1989), water 
(Eichelberger et al. 1983; NIOSH 1983; Rhoades et al. 1983, soil (NIOSH 1983), and foods (Fine et al. 
1976) are very limited. More information on the accuracy, precision, and sensitivity for these methods is 
needed to determine if these methods are sensitive enough to measure background levels in the 
environment, as well as levels at which health effects might occur. Research investigating the relationship 
between levels measured in air, water, soil, and foods and observed health effects could increase our 
confidence in existing methods and/or indicate where improvements are needed. 
6.3.2  On-going Studies 
No on-going studies were located for N-nitrosodiphenylamine. 
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7. REGULATIONS AND ADVISORIES 
The international, national. and state regulations and guidelines regarding N-nitrosodiphenylamine in air, 
water, and other media are summarized in Table 7-l. 
EPA has not derived an inhalation reference concentration or an oral reference dose for 
N-nitrosodiphenylamine (IRIS 1990). The quantitative estimate of carcinogenic risk from oral exposure 
is 4.9x10-3 mg/kg/day (IRIS 1990), based on transitional cell carcinomas of the bladder in rats exposed to 
N-nitrosodiphenylamine in the diet (NCI 1979). N-Nitrosodiphenylamine has a weight-of-evidence 
classification of B2, which indicates a probable human carcinogen (IRIS 1990). 
N-Nitrosodiphenylamine is on the list of chemicals appearing in “Toxic Chemicals Subject to Section 313 of 
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption Coefficient (KOC) -- The ratio of the amount of a chemical adsorbed per unit weight of organic 
carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at 
a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil 
or sediment. 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen -- A chemical capable of inducing cancer. 
Ceiling Value -- A concentration of a substance that should not be exceeded, even instantaneously. 
Clastogen -- A substance which causes a break in the DNA molecule that is observable at the chromosome 
level. 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Developmental Toxicity -- The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurred. The terms, as used here, include malformations and variations, altered growth, and in 
utero death. 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a chemical substance based on 
health effects information. A health advisory is not a legally enforceable federal standard, but serves as 
technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental concentration of a 
contaminant from which one could escape within 30 min without any escape-impairing symptoms or 







Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity -- The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
In vitro -- Isolated from the living organism and artificially maintained, as in a test tube. 
In vivo -- Occurring within the living organism. 
Lethal Concentration(LO) (LC LO) -- The lowest concentration of a chemical in air which has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC 50) -- A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO) -- The lowest dose of a chemical introduced by a route other than inhalation that 
is expected to have caused death in humans or animals. 
Lethal Dose(50) (LD 50) -- The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time (50) (LT 50) -- A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in a study, or group of 
studies, that produces statistically or biologically significant increases in frequency or severity of adverse 
effects between the exposed population and its appropriate control. 
Malformations -- Permanent structural changes that may adversely affect survival, development, or function. 
Minimal Risk Level -- An estimate of daily human exposure to a dose of a chemical that is likely to be 
without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen -- A substance that causes mutations. A mutation is a change in the genetic material in a body 
cell. Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity -- The occurrence of adverse effects on the nervous system following exposure to chemical. 
No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which there were no statistically 
or biologically significant increases in frequency or severity of adverse effects seen between the exposed 
population and its appropriate control. Effects may be produced at this dose, but they are not considered 
to be adverse. 
Octanol-Water Partition Coefficient (K OW) -- The equilibrium ratio of the concentrations of a chemical in 











Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace air averaged over an S-hour 
shift. 
q1* -- The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and µg/m3 
for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal and 
human studies) by a consistent application of uncertainty factors that reflect various types of data used to 
estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire 
database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer. 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities 
are measured over a 24-hour period. 
Reproductive Toxicity -- The occurrence of adverse effects on the reproductive system that may result from 
exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Short-Term Exposure Limit (STEL) -- The maximum concentration to which workers can be exposed for 
up to 15 min continually. No more than four excursions are allowed per day, and there must be at least 
60 min between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity -- This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen -- A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV) -- A concentration of a substance to which most workers can be exposed 
without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-Weighted Average (TWA) -- An allowable exposure concentration averaged over a normal S-hour 
workday or 40-hour workweek. 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route other than inhalation, which 





Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD from experimental data. UFs 
are intended to account for (1) the variation in sensitivity among the members of the human population, 
(2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating 
from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using 











Public Health Statement 
This chapter of the profile is a health effects summary written in nontechnical hanguage. Its intended audience is 
the general public especially people living in the vicinity of a hazardous waste site or substance release. If the 
Public Health Statement were removed from the rest of the document, it would still communicate to the lay public 
essential information about the substance. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are 
written in a question and answer format. The answer to each question includes a sentence that will direct the reader 
to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects by duration of exposure 
and endpoint and to illustrate graphically levels of exposure associated with those effects. All entries in these tables 
and figures represent studies that provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels 
(NOAELs), Lowest-Observed- Adverse-Effect Levels (LOAELs) for Less Serious and Serious health effects, or 
Cancer Effect Levels (CELs). In addition, these tables and figures illustrate differences in response by species, 
Minimal Risk Levels (MRLs) to humans for noncancer end points, and EPA’s estimated range associated with an 
upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE tables and figures can be 
used for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and 
figures should always be used in conjunction with the text. 
The legends presented below demonstrate the application of these tables and figures. A representative example of 
LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends correspond to the numbers 
in the example table and figure. 
LEGEND 
See LSE Table 2-1 
(1).	  Route of Exposure One of the first considerations when reviewing the toxicity of a substance using these 
tables and figures should be the relevant and appropriate route of exposure. When sufficient data exist, 
three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on 
the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3, 
respectively). LSE figures are limited to the inhalation (LSE Figure 2-l) and oral (LSE Figure 2-2) routes. 
(2)	 Exposure Duration Three exposure periods: acute (14 days or less); intermediate (15 to 364 days); and 
chronic (365 days or more) are presented within each route of exposure. In this example, an inhalation 









(3)	 Health Effect  The major categories of health effects included in LSE tables and figures are death. 
systemic, immunological, neurological. developmental, reproductive. and cancer.  NOAELs and LOAELs 
CM be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in 
the “System” column of the LSE table. 
(4)	 Key to Figure Each key number in the LSE table links study information to one or more data points using 
the same key number in the corresponding LSE figure. In this example, the study represented by key 
number 18 has been used to define a NOAEL and a Less Serious LOAEL (also see the two “18r” data 
points in Figure 2-l). 
(5)	  Species The test species, whether animal or human, are identified in this column. 
(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure regimen are 
provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this 
case (key number IQ, rats were exposed to [substance x] via inhalation for 13 weeks, 5 days per week, for 6 
hours per day. 
(7)	 System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. “Other” 
refers to <any systemic effect (e.g., a decrease in body, weight) not covered in these systems. In the 
example of key number 18, one systemic effect (respiratory) was investigated in this study. 
(8)	 NOAEL A No Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the 
respiratory system which was used to derive an intermediate exposure, inhalation h4RL of 0.005 ppm (see 
footnote “b”). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest exposure level used in the study 
that caused a harmful health effect. LOAELs have been classified into “Less Serious” and “Serious” 
effects. These distinctions help readers identify the levels of exposure at which adverse health effects first 
appear and the gradation of effects with increasing dose. A brief description of the specific end point used 
to quantify the adverse effect accompanies the LOAEL. The “Less Serious” respiratory effect reported in 
key number 18 (hyperplasia) occurred at a LOAEL of 10 ppm. 
(10)	 Reference The complete reference citation is given in Chapter 8 of the profile. 
(11)	  CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiological studies. CELs are always considered serious effects. The 
LSE tables and figures do not contain NOAELs for cancer, but the text may report doses which did not 
cause a measurable increase in cancer. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in the 










See LSE Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader 
quickly compare health effects according to exposure levels for particular exposure duration. 
(13)	 Exposure Duration The same exposure periods appear as in the LSE table. In this example, health effects 
observed within the intermediate and chronic exposure periods rare illustrated. 
(14)	 Health Effect These are the categories of health effects for which reliable quantitative data exist. The 
same health effects appear in the LSE table. 
(15)	 Levels of Exposure Exposure levels for each health effect in the LSE tables are graphically displayed in the 
LSE figures. Exposure levels are reported on the log scale “y” axis. Inhalation exposure is reported in 
mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16)	 NOAEL In this example, 1% NOAEL is the critical end point for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates a 
NOAEL for the test species (rat). The key number 18 corresponds to the entry in the LSE table. The 
dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the 
Table) to the MRL of 0.005 ppm (see footnote “b” in the LSE table). 
(17)	 CEL Key number 38r is one of three studies for which Cancer Effect Levels (CELs) were derived. The 
diamond symbol refers to a CEL for the test species (rat). The number 38 corresponds to the entry in the 
LSE table. 
(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the upper-bound for 
lifetime cancer risk of 1 in 10,000 to 1 in 10.000,000. These risk levels are derived from EPA’s Human 
Health Assessment Group’s upper-bound estimates of the slope of the cancer dose response curve at low 
dose levels (q1*). 








    





Chapter 2 (Section 2.4) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary bnsed on evaluations of existing 
toxicologicaL epidemioIogical, and toxicokinetic information. This summary is designed to present interpretive, 
weight-of-evidence discussions for human he‘alth end points by addressing the following questions. 
1 . What effects are known to occur in humans? 
2 . What effects observed in animals are likely to be of concern to humans? 
3 . What exposure conditions are likely to be of concern to humans, especially ‘around hazardous waste 
sites? 
The section discusses health effects by end point. Human data are presented first, then animal data. Both are 
organized by route of exposure (inhalation, oral, and dermal) and by duration (acute, intermediate, and chronic). In 
vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in 
this section. If data are located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing 
toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform 
cancer risk assessments. MRLs for noncancer end points if derived, and the end points from which they were 
derived are indicated and discussed in the appropriate section(s). 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are 
identified in the Identification of Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information was available, MRLs were derived. MRLs are specific for route 
(inhalation or oral) and duration (acute, intermediate, or chronic) of exposure. Ideally, MRLs can be derived from 
all six exposure scenarios (e.g., Inhalation - acute, -intermediate, -chronic; Oral - acute, -intermediate, - chronic). 
These MRL are not meant to support regulatory action, but to aquaint health professionals with exposure levels at 
which adverse health effects are not expected to occur in humans. They should help physicians and public health 
officials determine the safety of a community living neara substance emission, given the concentration of a 
contaminant in air or the estimated daily dose received via food or water. MRLs are based largely on toxicological 
studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicological information on which the number is based. Section 2.4, 
“Relevance to Public Health,” contains basic information known about the substance. Other sections such as 2.6, 
“Interactions with Other Chemicals” and 2.7, “Populations that are Unusually Susceptible” provide important 
supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version 
of the risk assessment methodology used by the Environmental Protection Agency (EPA) (Barnes and Dourson, 
1988; EPA 1989a) to derive reference doses (RfDs) for lifetime exposure. 
   
 






   
  






To derive an MRL. ATSDR generally selects the end point which, in its best judgement, represents the most 
sensitive human health effect for a given exposure route and duration. ATSDR cannot m‘ake this judgement or 
derive an MRL unless information (quantitative or qualitative) is available for all potential effects (e.g., systemic. 
neurological, and developmental). In order to comp,are NOAELs and LOAELs for specific end points, all 
inhalation exposure levels are adjusted for 24hr exposures and all intermittent exposures for inhalation and oral 
routes of intermediate and chronic duration are adjusted for continous exposure (i.e., 7 days/week). If the 
information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using 
the most sensitive species (when information from multiple species is available) with the highest NOAEL that does 
not exceed any adverse effect levels. The NOAEL is the most suitable end point for deriving an MRL. When a 
NOAEL is not available, a Less Serious LOAEL can be used to derive an MRL, and an uncertainty factor (UF) of 
10 is employed. MRLs are not derived from Serious LOAELs. Additional uncertainty factors of 10 each are used for 
human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused 
by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, 
these individual uncertainty factors are multiplied together. The product is then divided into the adjusted inhalation 
concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific 
MRL are provided in the footnotes of the LSE Tables. 







